[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 316
1. Chamberlain MC, Glantz MJ: Cerebrospinal fluid-disseminated meningioma. Cancer; 2005 Apr 1;103(7):1427-30
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid-disseminated meningioma.
  • BACKGROUND: Intracranial meningiomas are common and comprise 20% of all primary brain tumors.
  • Meningiomas infrequently metastasize; however, to the authors' knowledge there are limited data regarding the spread of disease through cerebrospinal fluid (CSF).
  • METHODS: Eight of 200 consecutive patients (4%) with meningiomas manifested CSF dissemination.
  • All patients had undergone prior surgery (range, one to five surgeries; median, two surgeries), radiotherapy (involved-field radiotherapy in seven patients and stereotactic radiotherapy in six patients), and chemotherapy (hydroxyurea in eight patients).
  • Multiple sites of metastases were seen in all patients and were both within the nervous system (subarachnoid or ventricular tumor: intracranial in eight patients, spinal cord in four patients) and extraneural (subcutaneous, cervical lymph nodes, orbit, or pulmonary in five patients).
  • Treatment utilized both systemic chemotherapy (temozolomide in four patients, irinotecan in three patients, hydroxyurea in three patients, interferon-alpha in two patients, and doxorubicin plus ifosfamide in one patient) and intraventricular chemotherapy (liposomal cytosine arabinoside in seven patients, thiotepa in one patient, and busulfan in one patient).
  • RESULTS: Treatment-related toxicity was seen in eight patients, including chemical meningitis in eight patients (Grade 2), neutropenia in five patients (Grade 2 in four patients and Grade 3 in one patient), fatigue in one patient (Grade 2), and gastrointestinal toxicity in one patient (Grade 2).
  • The best response was stable disease in seven patients and progressive disease in one patient.
  • The median survival was 5.5 months, and 3 patients were alive with disease at the time of last follow-up.
  • CONCLUSIONS: The treatment of CSF-disseminated meningioma, although feasible and comparatively nontoxic, was associated with modest outcomes despite combined systemic and intraventricular chemotherapy.
  • [MeSH-major] Meningioma / secondary
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Cerebrospinal Fluid / cytology. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Skin Neoplasms / secondary. Spinal Cord Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15690330.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Puduvalli VK, Li JT, Chen L, McCutcheon IE: Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res; 2005 Feb 15;65(4):1547-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis in primary meningioma cultures by fenretinide.
  • Fenretinide, a synthetic retinoid that induces apoptosis in tumor cells in vitro, is being evaluated in clinical trials as a chemotherapeutic agent against several malignancies.
  • Due to its ease of administration, long-term tolerability, and low incidence of long-term side effects, we explored its potential as a therapeutic agent against meningiomas by examining its efficacy in vitro against such cells in primary culture.
  • Cells, cultured from freshly resected benign, atypical, or malignant meningiomas, were exposed to fenretinide (10 mumol/L).
  • Treatment effects were assessed using flow cytometry, Western blot analysis, semiquantitative reverse transcription-PCR for retinoid receptor expression, and changes in insulin-like growth factor-I (IGF-I)-induced proliferation.
  • Fenretinide induced apoptosis in the three grades of meningioma primary cells tested, as shown by the appearance of a sub-G(1) fraction in flow cytometric analysis and by the detection of poly-adenosyl ribonucleotidyl phosphorylase cleavage indicating caspase activation.
  • Fenretinide treatment also increased levels of the death receptor DR5 and caused mitochondrial membrane depolarization.
  • IGF-I-induced proliferation in the meningioma cells was abolished by fenretinide.
  • We conclude that fenretinide induces apoptosis in all three histologic subtypes of meningioma and exerts diverse cellular effects, including DR5 up-regulation, modulation of retinoid receptor levels, and inhibition of IGF-I-induced proliferation.
  • These results provide preliminary evidence that fenretinide has activity against meningiomas and suggest that further studies are warranted to explore its potential as a therapeutic agent against meningiomas.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Fenretinide / pharmacology. Meningioma / drug therapy
  • [MeSH-minor] Humans. Insulin-Like Growth Factor I / antagonists & inhibitors. Insulin-Like Growth Factor I / pharmacology. Membrane Potentials / drug effects. Mitochondria / drug effects. Mitochondria / physiology. Polyribonucleotide Nucleotidyltransferase / metabolism. Receptors, Retinoic Acid / biosynthesis. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / biosynthesis. Retinoid X Receptor alpha / biosynthesis. Up-Regulation / drug effects

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735044.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Retinoic Acid; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / Retinoid X Receptor alpha; 0 / TNFRSF10B protein, human; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor gamma; 187EJ7QEXL / Fenretinide; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.7.8 / Polyribonucleotide Nucleotidyltransferase
  •  go-up   go-down


3. Falavigna A, Santos JA, Chimelli L, Ferraz FA, Bonatelli Ad Ade P: Anaplastic meningioma: case report. Arq Neuropsiquiatr; 2001 Dec;59(4):939-43
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma: case report.
  • Intracranial meningiomas continue to challenge our best clinical efforts to eliminate them once discovered and deemed appropriate for treatment.
  • Malignant meningiomas constitute 10% to 15% of all meningiomas and limited information exists regarding adjuvant treatment.
  • The external whole brain irradiation is recommended.
  • Traditional chemotherapy has proven ineffective; thus, new chemotherapeutic agents and new methods of delivery should be developed.
  • Immunotherapy may be considered for patients with malignant meningiomas when all others previous treatment have failed.
  • We report a case of anaplastic papillary meningioma.
  • A computerized tomography and magnetic resonance image demonstrated a large left temporo-occipital mass with diffuse contrast enhancement and extensive surrounding edema.
  • The tumor and the infiltrated dura were radically removed.
  • The treatment was complemented by external whole brain radiation.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11733842.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 28
  •  go-up   go-down


Advertisement
4. Chargari C, Védrine L, Bauduceau O, Le Moulec S, Ceccaldi B, Magné N: Reapprasial of the role of endocrine therapy in meningioma management. Endocr Relat Cancer; 2008 Dec;15(4):931-41
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reapprasial of the role of endocrine therapy in meningioma management.
  • Recurrent meningiomas constitute an uncommon but significant problem after standard therapy failure.
  • Speculation that meningiomas may be subject to endocrine influence was supported by both immunohistochemical analyses and epidemiological data.
  • Therefore, alternative strategies such as endocrine therapy have been suggested.
  • Although evidence of consistent findings for the role of specific hormonal exposures is mounting, there are numerous discrepancies about the mitogenic effect of hormonal manipulation on meningioma cells.
  • A better understanding of the molecular mechanisms involved in meningioma pathogenesis may not only lead to the identification of novel diagnostic and prognostic markers but may also facilitate the development of new pathogenesis-based targeted strategies.
  • This review of literature aims to summarize the present state of the art of endocrine therapy in the management of meningiomas, in order to establish whether hormonotherapy could be included in the therapeutic strategy for unresectable and/or progressive tumours in previously irradiated meningioma patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Meningeal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632875.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 78
  •  go-up   go-down


5. Saeger W: [Pituitary gland tumors]. Pathologe; 2003 Jul;24(4):255-64
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pituitary gland tumors].
  • Pituitary adenomas must be clearly differentiated from other tumors of the sellar region (especially meningiomas, granular cell tumors, chordomas and germinomas), which may look very similar.
  • This sub-classification is not necessary in every case, but must be performed if unusual findings are observed during surgery or if surgery is unsuccessful and radiation or drug-therapy is planned.
  • We differentiated monohormonal densely or sparsely granulated GH-cell adenomas, monohormonal sparsely or very rarely densely granulated prolactin cell adenomas, monohormonal densely or sparsely ACTH-cell adenomas, monohormonal TSH-cell adenomas and FSH/LH cell adenomas from bihormonal adenomas of mammosomatotroph or GH/prolactin cell type or of the acidophil stem cell adenoma type.
  • These appear as subtypes of one entity deriving from the gonadotroph cell type.
  • Craniopharyngiomas are classified into adamantinous and papillary types, which are not only structurally but also clinically different.
  • [MeSH-minor] Adenoma / pathology. Adenoma / secretion. Diagnosis, Differential. Humans. Pituitary Hormones / secretion. Sella Turcica / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1981;54(3):257-60 [6167138.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1313-8; discussion 1318-9 [11126902.001]
  • [Cites] Pathol Res Pract. 1991 Jun;187(5):632-6 [1923959.001]
  • [Cites] Endocr Pathol. 1996 Spring;7(1):21-35 [12114677.001]
  • [Cites] Pathol Res Pract. 1988 Sep;183(5):592-5 [3237549.001]
  • [Cites] Pathologe. 1997 Nov;18(6):419-24 [9451729.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):135-143 [12114649.001]
  • [Cites] Exp Clin Endocrinol. 1988 Aug;91(3):341-9 [3251773.001]
  • [Cites] Endocr Pathol. 2000 Autumn;11(3):215-227 [12114694.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 May;128(5):411-7 [8317187.001]
  • [Cites] Gen Diagn Pathol. 1995 Oct;141(2):81-92 [8548598.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(2):147-51 [11459086.001]
  • [Cites] Pituitary. 1999 May;1(3-4):213-20 [11081200.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jan;110(1):72-5 [3510059.001]
  • [Cites] Pathol Res Pract. 1993 Nov;189(9):1044-51 [8302723.001]
  • [Cites] Pathologe. 2001 Sep;22(5):296-309 [11572110.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(4):417-31 [2426859.001]
  • [Cites] Neurosurgery. 1993 Nov;33(5):920-4; discussion 924-5 [8264895.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Apr;54(4):479-84 [11318783.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):677-83; discussion 683-4 [7596496.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;394(3):255-67 [6280372.001]
  • (PMID = 14513271.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Pituitary Hormones
  • [Number-of-references] 27
  •  go-up   go-down


6. Norden AD, Drappatz J, Wen PY: Targeted drug therapy for meningiomas. Neurosurg Focus; 2007;23(4):E12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted drug therapy for meningiomas.
  • Although advances in surgery, radiation therapy, and stereotactic radiosurgery have significantly improved the treatment of meningiomas, there remains an important subset of patients whose tumors are refractory to conventional therapy.
  • Treatment with traditional chemotherapeutic agents has provided minimal benefit.
  • In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961036.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors
  • [Number-of-references] 142
  •  go-up   go-down


7. Dufour H, Métellus P, Manera L, Fuentes S, Do L, Grisoli F: Spontaneous vertex extradural hematoma: considerations about causes. Case report and review of the literature. J Neurosurg; 2001 Apr;94(4):633-6
MedlinePlus Health Information. consumer health - Bone Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroimaging workup disclosed a homogeneous mass at the vertex, which first was diagnosed as vertex meningioma.
  • Anticonvulsant drug therapy was administered and the patient was discharged.
  • Two months later the patient was examined in our neurosurgery department for additional therapeutic recommendations.
  • A complete blood-coagulation study displayed no evidence of abnormality.
  • The final diagnosis was spontaneously occurring vertex EDH.
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Seizures / drug therapy. Seizures / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11302666.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  • [Number-of-references] 51
  •  go-up   go-down


8. Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, Keilhoff G, Evert M, Paulus W, Gutmann DH, Lal A, Mawrin C: Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol; 2010 Aug;12(8):844-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatty acid synthase as a novel target for meningioma therapy.
  • High levels of fatty acid synthase (FAS) expression have been reported in hormone receptor-positive tumors, including prostate, breast, and ovarian cancers, and its inhibition reduces tumor growth in vitro and in vivo.
  • Similar to other hormone receptor-positive tumor types, meningiomas are progesterone receptor- and estrogen receptor-immunoreactive brain tumors.
  • To define the role of FAS in human meningioma growth control, we first analyzed the FAS expression using a tissue microarray containing 38 meningiomas and showed increased FAS expression in 70% of atypical WHO grade II and anaplastic WHO grade III meningiomas compared with 10% of benign WHO grade I tumors.
  • We next confirmed this finding by real-time PCR and Western blotting.
  • Second, we demonstrated that treatment with the FAS inhibitor, cerulenin (Cer), significantly decreased meningioma cell survival in vitro.
  • Third, we showed that Cer treatment reduced FAS expression by modulating Akt phosphorylation (activation).
  • Fourth, we demonstrated that Cer treatment of mice bearing meningioma xenografts resulted in significantly reduced tumor volumes associated with increased meningioma cell death.
  • Collectively, our data suggest that the increased FAS expression in human meningiomas represents a novel therapeutic target for the treatment of unresectable or malignant meningioma.
  • [MeSH-major] Cerulenin / pharmacology. Fatty Acid Synthases / metabolism. Fatty Acid Synthesis Inhibitors / pharmacology. Meningeal Neoplasms / enzymology. Meningioma / enzymology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Cell Survival / drug effects. DNA Fragmentation / drug effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Mice, SCID. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2000 May;48(5):613-22 [10769045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3450-4 [10716717.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):153-7 [11205903.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1493-9 [11245456.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1626-35 [11920521.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):132-7 [12531699.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7794-808 [14560023.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7330-7 [14612531.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):411-22 [15254710.001]
  • [Cites] Ann Neurol. 2004 Aug;56(2):295-8 [15293284.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36608-15 [15220355.001]
  • [Cites] J Biochem. 1989 May;105(5):751-5 [2666407.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2243-9 [2804914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6379-83 [8022791.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1189-93 [8640795.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):45-51 [8986532.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4589-93 [9494573.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):L381-90 [10444533.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):99-108 [15543204.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):39-46 [15489885.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Pathol. 2005 Jun;206(2):214-9 [15880754.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4074-82 [15930342.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3574-82 [15806173.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Clin Neuropathol. 2005 Jul-Aug;24(4):175-83 [16033134.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1163-71 [15965488.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):869-78 [16969344.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):735-45 [17234785.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):763-77 [17882277.001]
  • [Cites] Biomed Pharmacother. 2007 Oct;61(9):578-87 [17904792.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):314-22 [18172325.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • (PMID = 20511185.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acid Synthesis Inhibitors; 0 / RNA, Messenger; 17397-89-6 / Cerulenin; EC 2.3.1.85 / Fatty Acid Synthases
  • [Other-IDs] NLM/ PMC2940685
  •  go-up   go-down


9. Cimmino A, Giangaspero F, Pennella A, Serio G, De Tomasi A, Colamaria A, Ricco R: [Oncocytic meningioma. Case report]. Pathologica; 2000 Apr;92(2):82-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oncocytic meningioma. Case report].
  • [Transliterated title] Meningioma oncocitario. Descrizione di un caso.
  • Among the histological variants of meningiomas the oncocytic subtype is rarely observed.
  • Up-today, only six cases of oncocytic meningioma are described.
  • This subtype of meningiomas shows an aggressive behavior and recurrences are more frequent.
  • We describe a case of oncocytic meningioma in a 78-years-old woman.
  • The patient had a history of breast cancer diagnosed 9 years before the brain biopsy; bilateral mastectomy and adjuvant chemotherapy was performed.
  • Neoplastic cells were arranged in sheets and nests delimited by thin fibrous septa rich in vessels.
  • The rarity of oncocytic meningiomas is underlined with only six cases described in the world literature.
  • The immunophenotypic profile and the differential diagnosis of the neoplasm is discussed and the concept of oncocytic meningioma as a distinct entity of tumour is emphasized.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Brain Edema / etiology. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Breast Neoplasms. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / secondary. Carcinoma, Medullary. Diagnosis, Differential. Female. Humans. Neoplasms, Second Primary

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10838873.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, Vecht C: Meningioma. Crit Rev Oncol Hematol; 2008 Aug;67(2):153-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma.
  • Meningiomas are mostly benign tumours originating from the arachnoid cap cells, represent 13-26% of all intracranial tumours.
  • Five-year survival for typical meningiomas exceeds 80%, but is poorer (5-year survival <60%) in malignant and atypical meningiomas.
  • Complete surgical excision is the standard treatment.
  • Radiotherapy is currently used in the clinical practice in atypical, malignant or recurrent meningioma at a total dose of 45-60Gy.
  • However, the role of adjuvant irradiation is still controversial and has to be compared in a randomised prospective setting with a policy of watchful waiting.
  • Radiosurgery has gained more and more importance in the management of meningiomas, especially in meningiomas that cannot be completely resected as for many skull base meningiomas.
  • Medical therapy for patients with recurrent, progressive and symptomatic disease after repeated surgery, radiosurgery and radiotherapy is investigational.
  • Hormonal therapy with progesterone antagonists has shown modest results, while chemotherapy with hydroxyurea appears moderately active.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342535.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 184
  •  go-up   go-down


11. Newton HB, Slivka MA, Stevens C: Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol; 2000 Sep;49(2):165-70
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydroxyurea chemotherapy for unresectable or residual meningioma.
  • Meningiomas represent 18-20% of all intracranial tumors and have a 10-year recurrence rate of 20-50%, despite aggressive surgery and irradiation.
  • In addition, many tumors are not amenable to surgery due to their deep location or proximity to delicate structures.
  • Chemotherapy is being explored as another potential treatment option for unresectable or refractory meningiomas.
  • Hydroxyurea is an agent that inhibits ribonucleotide reductase and can induce apoptosis in meningioma cell cultures and animal models.
  • We have placed 17 patients with unresectable or residual meningioma on hydroxyurea chemotherapy (20 mg/kg/d orally).
  • Eleven patients had actively growing tumors or neurological progression at the onset of chemotherapy.
  • Fourteen of the 16 patients (88%) responded with stable disease ranging from 20 to 144+ weeks (median 80 weeks; 10 patients still accruing time).
  • Two patients had progressive disease after 10 weeks.
  • Hydroxyurea appears to have modest activity against meningiomas and should be considered in patients with unresectable tumors or large residual tumors following surgical resection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Hemoglobins / analysis. Humans. Leukocytes / metabolism. Male. Middle Aged. Neoplasm, Residual. Platelet Count

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pharmacother. 1999 Jul-Aug;33(7-8):816-32 [10466912.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Natl Cancer Inst. 1994 Sep 7;86(17):1286-96 [8064887.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Semin Oncol. 1987 Mar;14(1):65-74 [3823917.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurosurg. 1997 May;86(5):845-52 [9126901.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Cancer Invest. 1997;15(4):372-81 [9246161.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • (PMID = 11206012.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hemoglobins; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


12. Lusis E, Gutmann DH: Meningioma: an update. Curr Opin Neurol; 2004 Dec;17(6):687-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma: an update.
  • PURPOSE OF REVIEW: Recent clinical and molecular research has shed new light on the biology of meningiomas--a common but understudied CNS neoplasm.
  • This review will focus on recent advances and their significance for future research and treatment.
  • RECENT FINDINGS: Meningiomas represent the second most common brain tumor in adults, and while improved diagnostic modalities are available, these tumors remain underreported.
  • Radiosurgery is an effective adjuvant therapy against meningioma; however, no effective chemotherapy exists.
  • In addition to histologic grading and estimates of the extent of resection, biomarkers, such as progesterone receptor, cyclooxygenase 2, S100A5 and ornithine decarboxylase may be useful in predicting tumor recurrence and/or progression potential in patients with meningioma.
  • On the genetic level, cytogenetic losses on chromosomes 1, 7, 10 and 14 and telomerase activation are observed in clinically aggressive meningioma, whereas monosomy 22 is a common early molecular event in tumor formation.
  • Several candidate growth regulatory genes have been identified, including the Neurofibromatosis 2 (NF2), Tumor Suppressor in Lung Cancer-1 (TSLC1), Protein 4.1B, p53/MDM2 and S6-Kinase genes.
  • The roles of these genes in meningioma formation and progression, as well as the clinical implications of these genetic changes, are discussed.
  • SUMMARY: The recent insights into the molecular biology and genetics of meningioma provide new avenues for basic science research aimed at understanding the mechanisms underlying meningioma formation and malignant progression.
  • These advances may be useful in improving our ability to predict clinical outcome and developing targeted therapies to improve outcomes in patients with clinically aggressive meningiomas.
  • [MeSH-major] Meningeal Neoplasms / enzymology. Meningeal Neoplasms / genetics. Meningioma / enzymology. Meningioma / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / genetics. Cell Transformation, Neoplastic / genetics. Chromosome Aberrations. Disease Progression. Gene Expression Regulation, Neoplastic / genetics. Humans. Prognosis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542977.001).
  • [ISSN] 1350-7540
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 38
  •  go-up   go-down


13. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol; 2006 Jul;78(3):271-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent meningioma.
  • BACKGROUND: A prospective Phase II study of irinotecan (CPT-11) in adult patients with recurrent surgery and radiotherapy-refractory WHO Grade I meningioma.
  • METHODS: Sixteen patients (5 men; 11 women) ages 48-70 years (median 62.5), with recurrent meningioma were treated.
  • All patients had previously been treated with surgery (complete in 4; partial in 9; biopsy in 3) and involved-field radiotherapy (median dose 54 Gy; 12 following first surgery and 4 following second surgery).
  • No patient was treated with prior chemotherapy.
  • One patient developed neutropenic fever without bacteriologic confirmation.
  • No treatment-related deaths occurred.
  • No patient demonstrated a neuroradiographic complete or partial response (PR), 13 patients (81%) demonstrated stable disease but disease progressed after 2 cycles of CPT-11, and 3 patients (19%) had progressive disease (PD) following a single cycle of CPT-11.
  • Time to tumor progression ranged from 2.5 to 5.0 months (median 5.0 months).
  • Using CPT-11 in this moderately toxic dose schedule failed to demonstrate efficacy in this cohort of adult patients with recurrent surgery and radiotherapy-refractory meningioma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Meningioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Aged. Agranulocytosis / chemically induced. Anticonvulsants / therapeutic use. Diarrhea / chemically induced. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Leukopenia / chemically induced. Male. Middle Aged. Treatment Failure

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1994 Nov;81(5):666-75 [7931612.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] J Neurooncol. 1990 Feb;8(1):61-5 [2319292.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):42-9 [10413154.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurosurg. 1997 May;86(5):845-52 [9126901.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):545-7 [2398385.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):65-72 [12134934.001]
  • [Cites] Neurology. 1997 May;48(5):1459-62 [9153494.001]
  • [Cites] Neurology. 1998 Dec;51(6):1718-20 [9855530.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Lancet. 1995 Feb 4;345(8945):331 [7837901.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):187-90 [8283254.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):552-9 [2002367.001]
  • (PMID = 16628476.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Norden AD, Drappatz J, Wen PY: Advances in meningioma therapy. Curr Neurol Neurosci Rep; 2009 May;9(3):231-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in meningioma therapy.
  • Meningiomas are the most common primary brain tumors in adults.
  • Surgical resection is curative when complete removal of a benign meningioma is possible.
  • Incompletely resected tumors and high-grade lesions are frequently treated with fractionated radiotherapy or stereotactic radiosurgery.
  • High-grade meningiomas tend to recur following maximal treatment with surgery and radiation.
  • Chemotherapeutic agents, including hydroxyurea, have been used for recurrent disease with marginal efficacy.
  • As the molecular pathogenesis of meningiomas is elucidated, targeted drug therapies may prove useful.
  • Angiogenesis inhibitors, agents that target fundamental cell signaling pathways, somatostatin analogues, and a variety of other molecular treatments appear promising.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Humans. Radiosurgery / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zentralbl Neurochir. 2005 Feb;66(1):17-23 [15744624.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):161-2 [15762200.001]
  • [Cites] J Biomed Opt. 2005 Nov-Dec;10(6):064026 [16409091.001]
  • [Cites] N Engl J Med. 2007 Dec 6;357(23):2411-2 [18057351.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5):1048-59; discussion 1060-1 [18091281.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):279-82 [18182668.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):438-46 [17704362.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):251-9 [18365142.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):471-6 [17580362.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5295-303 [16707455.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1655-61 [17684142.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Neurosurgery. 2007 May;60(5):787-98; discussion 787-98 [17460514.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):107-13; discussion 107-13 [15987576.001]
  • [Cites] Brain. 2008 Mar;131(Pt 3):606-15 [17940085.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E9 [17961046.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E11 [17961035.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] J Neurooncol. 2007 May;83(1):33-8 [17245625.001]
  • [Cites] Neoplasia. 2008 Nov;10(11):1204-12 [18953429.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Nov;187(1):25-7 [18992637.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):87-93 [18617056.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Neurosurgery. 1997 May;40(5):1016-26 [9149260.001]
  • [Cites] J Neurol. 2008 Jun;255(6):891-5 [18350353.001]
  • [Cites] Curr Med Chem. 2008;15(8):826-33 [18393851.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Neurosurgery. 2000 Apr;46(4):938-47; discussion 947-8 [10764269.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):487-92 [11235955.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17 (10 ):2663-70 [18843008.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):1034-40 [17564176.001]
  • [Cites] Hybridoma. 2001 Apr;20(2):131-6 [11394532.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6 Suppl 3):1115-21; discussion 1121-3 [18695533.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):147-56 [17594108.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):270-6 [18270339.001]
  • [Cites] Neurosurgery. 2008 Mar;62(3 Suppl 1):102-3; discussion 103-4 [18424972.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):604-12 [18516297.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E5 [17961042.001]
  • [Cites] Cancer Genet Cytogenet. 2008 May;183(1):14-20 [18474292.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93 [18294779.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):61-9; discussion 69-70 [18300892.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:62-7 [11143265.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2146-51 [18756531.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E2 [18447741.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3):495-503; discussion 503-4 [17881961.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):314-22 [18172325.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] BMC Cancer. 2006 Jun 07;6:152 [16759391.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E4 [17961041.001]
  • [Cites] BMC Genomics. 2007 Jan 12;8:16 [17222329.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1473-80 [17557299.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14(5):e5 [15669816.001]
  • (PMID = 19348712.001).
  • [ISSN] 1534-6293
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 81
  •  go-up   go-down


15. Marosi C, Hassler M, Hainfellner JA, Van Trotsenburg M, Preusser M, Birner P, Berger J: Microvessel density in progressive meningiomas and its influence on time to tumour recurrence. J Clin Oncol; 2004 Jul 15;22(14_suppl):1563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvessel density in progressive meningiomas and its influence on time to tumour recurrence.
  • : 1563 Background: Meningiomas constitute circumscribed intracranial tumours of limited resectability.
  • Adjuvant therapy is applied for growth control of incompletely resected tumours.
  • In such cases, chemotherapy is mandatory for tumour control, but hitherto used chemotherapy protocols showed unsatisfactory therapeutic effects.
  • METHODS: In order to develop new approaches based upon angiogenetic properties, we analysed systematically tumour vascularization in a set of 26 recurrent or inoperable meningiomas of 13 patients using the endothelial cell marker anti-CD34 for immunostaining.
  • RESULTS: MVD ranged from 22 to 149 vessels/standard area with a median of 50.5.
  • Clinically, the time to recurrence of tumours with high ( ≥ 50.5) MVD ( 28.4 months) was significantly shorter as compared to tumours with low MVD ( 72.1 months; p = 0.0136).
  • CONCLUSIONS: Our data indicate that MVD may influence the progression of meningiomas.
  • Due to the expression of VEGF messenger RNA and/or VEGF protein in all tumour samples, anti-VEGF strategies may exert a beneficial therapeutic effect in progressive meningiomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015730.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P: Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol; 2009 May 20;27(15_suppl):2062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas.
  • : 2062 Background: No effective treatment is available for recurrent meningiomas when surgical and radiation options are exhausted.
  • The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth.
  • In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients.
  • METHODS: Patients with recurrent histologically confirmed meningiomas and no more than two previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and eight (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 29%, 12-month PFS (PFS12) 0%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • For atypical/malignant tumors, PFS6 was 25%, PFS12 19%, OS6 81%, and OS12 68%.
  • Of 21 evaluable patients, there were no responses; eight patients (38%) had stable disease, and 13 (62%) had progressive disease.
  • Treatment was well-tolerated.
  • CONCLUSIONS: Neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma.
  • The role of EGFR inhibitors in meningiomas is unclear but evaluation of EGFR inhibitors in combination with other targeted molecular agents may be warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Pusiol T, Zorzi MG, Morichetti D, Piscioli I, Scialpi M: Peritoneal Malignant Psammomatous Mesothelioma. World J Oncol; 2010 Aug;1(4):179-181

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Psammoma bodies (PBs) are observed most commonly in papillary thyroid carcinoma, meningioma, and papillary serous cystadenocarcinoma of the ovary.
  • Contrast enhanced computed tomography showed fluid diffuse in peritoneal recesses, thick septa with micronodules in the greater omentum and adjacent enhancement of the thickened peritoneum.
  • The peritoneal biopsy revealed a superficial papillary growth of malignant epithelial-like cells with diffuse involvement of submesothelial tissues.
  • The patient was treated with chemotherapy (gemcitabine, vinorelbine, cisplatin).
  • PBs may represent an active biologic process ultimately leading to degeneration/death of tumor cells and retardation of growth of the neoplasm.
  • It may also serve as a barrier against the spread of tumor.
  • The behavior of serous psammocarcinoma is more closely similar to borderline serous tumor than to serous carcinoma.
  • Further studies are necessary to establish if massive deposition of PBs may define a new variant of psammomatous malignant mesothelioma with a favorable impact to the prognosis of usual psammomatous malignant mesothelioma, as well as in serous psammocarcinoma of the peritoneum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):285-94 [10680897.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):816-23 [10843283.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Histopathology. 2006 Feb;48(3):223-32 [16430468.001]
  • [Cites] Arch Gynecol Obstet. 2009 Jun;279(6):931-6 [18982336.001]
  • [Cites] Acta Med Port. 2002 Sep-Oct;15(5):383-6 [12645223.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Diagn Cytopathol. 2009 Jul;37(7):534-41 [19373908.001]
  • (PMID = 29147203.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Malignant mesothelioma / Psammoma bodies / Psammomatous malignant mesothelioma
  •  go-up   go-down


18. Weller M: [Chemotherapy for brain tumors in adult patients]. Nervenarzt; 2008 Feb;79(2):231-41
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for brain tumors in adult patients].
  • [Transliterated title] Chemotherapie von Hirntumoren bei Erwachsenen.
  • Chemotherapy has become a third major treatment option for patients with brain tumors, in addition to surgery and radiotherapy.
  • The role of chemotherapy in the treatment of gliomas is no longer limited to recurrent disease.
  • Several ongoing trials seek to define the role of chemotherapy in the primary care of other gliomas.
  • Outside such clinical trials chemotherapy is used in addition to radiotherapy, e.g., in anaplastic astrocytoma, medulloblastoma or germ cell tumors, or as an alternative to radiotherapy, e.g., in anaplastic oligodendroglial tumors or low-grade gliomas.
  • In contrast, there is no established role for chemotherapy in other tumors such as ependymomas, meningiomas or neurinomas.
  • Primary cerebral lymphomas are probably the only brain tumors which can be cured by chemotherapy alone and only by chemotherapy.
  • The chemotherapy of brain metastases follows the recommendations for the respective primary tumors.
  • Leptomeningeal metastases are treated by radiotherapy or systemic or intrathecal chemotherapy depending on their pattern of growth.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Genetic Markers / genetics. Humans. Prognosis. Promoter Regions, Genetic / genetics. Topotecan / adverse effects. Topotecan / therapeutic use. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2005 Feb;71(3):271-6 [15735916.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):44-55; discussion 55-6 [12182434.001]
  • [Cites] Neurologist. 2006 Jul;12(4):179-87 [16832237.001]
  • [Cites] Curr Treat Options Neurol. 2006 Jul;8(4):346-57 [16942677.001]
  • [Cites] Nervenarzt. 2003 Dec;74(12):1139-49 [14994756.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] J Neurol. 2005 Mar;252(3):291-9 [16189725.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1287-95 [17113463.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18253773.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 7M7YKX2N15 / Topotecan; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  •  go-up   go-down


19. Lin JW, Su FW, Wang HC, Lee TC, Ho JT, Lin CH, Lin YJ: Breast carcinoma metastasis to intracranial meningioma. J Clin Neurosci; 2009 Dec;16(12):1636-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma metastasis to intracranial meningioma.
  • Meningiomas and breast cancers are common tumors among women in the fifth to seventh decade.
  • However, metastasis from breast cancer to an intracranial meningioma is rare.
  • At that time, the pathological diagnosis was infiltrating ductal carcinoma.
  • She required adjuvant radiotherapy and chemotherapy for a local recurrence 7 years later.
  • Histopathological examination of the lesion revealed two distinct tumor types, meningioma and metastatic carcinoma of breast tissue origin.
  • Although meningiomas have well-known radiological features, other tumors, including metastases from breast cancers may simulate them.
  • In the clinical setting of previously diagnosed breast cancer, prompt craniotomy for removal of meningioma-like intracranial lesions is recommended to avoid missing the diagnosis of breast cancer metastasis which carries a poorer prognosis than meningioma and requires a different treatment strategy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Meningeal Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Keratins / metabolism. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766009.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


20. Lichtenbaum R, de Souza AA, Jafar JJ: Intratumoral hydrogen peroxide injection during meningioma resection. Neurosurgery; 2006 Oct;59(4 Suppl 2):ONS470-3; discussion ONS473
Hazardous Substances Data Bank. HYDROGEN PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral hydrogen peroxide injection during meningioma resection.
  • OBJECTIVE: Meningiomas, although histologically benign, pose a particular challenge to the neurosurgeon because of their extensive and exuberant vascularity.
  • Although anecdotally known to be useful, the use of hydrogen peroxide as an intracranial hemostatic agent in meningioma surgery has not been formally reported.
  • We report a technique of meningioma resection that uses intratumoral hydrogen peroxide injection, reducing the potential for blood loss and shortening resection times.
  • METHODS: Seventy-five patients underwent resection of a meningioma using the direct intratumoral H2O2 injection technique.
  • The locations of these meningiomas included convexity and cranial-based lesions.
  • RESULTS: The use of this technique greatly facilitated the removal of these tumors.
  • CONCLUSION: We demonstrate a previously unreported technique of meningioma resection that uses direct intratumoral hydrogen peroxide injection, potentially reducing blood loss, shortening resection times, and obviating the need for preoperative embolization.
  • [MeSH-major] Cerebral Hemorrhage / prevention & control. Hydrogen Peroxide / administration & dosage. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / surgery. Meningioma / drug therapy. Meningioma / surgery. Neurosurgical Procedures / adverse effects
  • [MeSH-minor] Combined Modality Therapy. Female. Hemostatics / administration & dosage. Humans. Injections, Intralesional. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041519.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


21. Soares D, Char G, Crandon I, Shaw H: Malignant meningioma with extension into the neck. West Indian Med J; 2000 Mar;49(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma with extension into the neck.
  • One per cent of all brain tumours and twenty per cent of meningiomas eventually develop an extracranial extension.
  • We report a case of malignant meningioma with extension into the neck of a 39-year-old male.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Meningeal Neoplasms / drug therapy. Meningioma / diagnosis
  • [MeSH-minor] Adult. Brain / pathology. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10786459.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAMAICA
  •  go-up   go-down


22. Fuentes S, Chinot O, Dufour H, Paz-Paredes A, Métellus P, Barrie-Attarian M, Grisoli F: [Hydroxyurea treatment for unresectable meningioma]. Neurochirurgie; 2004 Sep;50(4):461-7
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hydroxyurea treatment for unresectable meningioma].
  • [Transliterated title] Traitement des méningiomes par hydroxyurée.
  • BACKGROUND: Management of unresectable progressive meningioma remains controversial and constitutes a major challenge since therapeutic options including chemotherapy and hormone modulation are limited.
  • Recent data have suggested that hydroxyurea treatment may have an antitumoral effect.
  • The purpose of this prospective phase II study was to evaluate the efficacy of hydroxyurea treatment for unresectable progressive meningioma.
  • METHODS: From 1997 to 1999, consecutive patients presenting unresectable meningioma with clinically and/or neuroradiologically documented progression were considered for entry into this protocol.
  • Treatment consisted of continuous oral administration of hydroxyurea at a dose of 20 mg/kg per day.
  • Follow-up assessment included physical examination, computed tomography (CT), and magnetic resonance imaging (MRI) performed every three months, as well as regular blood testing.
  • Twenty-eight patients had undergone surgery following initial diagnosis.
  • The meningioma was located in the skull base in 67% of patients.
  • The eligible population included 36 patients with documented progressive disease at the time of inclusion; with progression documented clinically in 29 (67.5%) and/or radiologically in 20 (46%).
  • Progressive disease was observed clinically or radiologically in 26 patients (60.5%).
  • Of the eligible population (n=36), 2 achieved an objective response and 13 (36%) exhibited stabilization under hydroxyurea therapy, while 21 (58%) progressed under treatment.
  • Treatment was discontinued in 3 patients because of chronic skin toxicity in one and anemia and asthenia in two.
  • CONCLUSION: Hydroxyurea treatment is of marginal efficacy for meningioma and must not be considered as an alternative if radiotherapy or surgery is feasible.
  • New efficient medical treatments are still required for progressive meningiomas.
  • [MeSH-major] Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15547484.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


23. Johnson M, Toms S: Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol; 2005 Dec;64(12):1029-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?
  • These pathways have been extensively studied in gliomas but only recently analyzed in meningiomas.
  • This article reviews current research on the growth factor receptor-Ras-Raf-1-MEK-1-MAPK, PI3K-Akt/PKB, PLC-gamma1-PKC, phospholipase A2-cyclooxygenase, and TGF-beta receptor-Smad pathways that appear to regulate meningioma growth and inhibit apoptosis.
  • Sites along these receptor/kinase cascades that might be targeted by novel therapies are also discussed.
  • [MeSH-major] Meningeal Neoplasms / physiopathology. Meningioma / physiopathology. Mitosis. Receptors, Growth Factor / metabolism. Signal Transduction
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Cell Division / drug effects. Humans. Medical Oncology / trends


24. Newton HB: Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus; 2007;23(4):E11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydroxyurea chemotherapy in the treatment of meningiomas.
  • Meningiomas are slow growing, extraaxial tumors that derive from the arachnoidal cap cells of the meninges.
  • Resection remains the main modality of treatment and can be curative in some cases.
  • The role of chemotherapy continues to be defined, but should be considered for patients with inoperable or frequently recurring meningiomas.
  • Hydroxyurea, an inhibitor of ribonucleotide reductase, is one of the most active agents and is known to induce apoptosis in meningioma cells in vitro and in mouse xenografts.
  • Results of preliminary clinical studies suggest that hydroxyurea has modest activity against recurrent and inoperable meningiomas, and can induce long term stabilization in some patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961035.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 65
  •  go-up   go-down


25. Kashimura H, Inoue T, Ogasawara K, Arai H, Otawara Y, Kanbara Y, Ogawa A: Prediction of meningioma consistency using fractional anisotropy value measured by magnetic resonance imaging. J Neurosurg; 2007 Oct;107(4):784-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of meningioma consistency using fractional anisotropy value measured by magnetic resonance imaging.
  • OBJECT: Preoperative planning for meningiomas requires information about tumor consistency as well as location and size.
  • In the present study the authors aimed to determine whether the fractional anisotropy (FA) value calculated on the basis of preoperative magnetic resonance (MR) diffusion tensor (DT) imaging could predict meningioma consistency.
  • METHODS: In 29 patients with intracranial meningiomas, MR DT imaging was performed preoperatively, and the FA values of the tumors were calculated.
  • Tumor consistency was intraoperatively determined as hard or soft, and the histological diagnosis of the tumor was established.
  • RESULTS: Of the 29 tumors, 11 were classified as hard and 18 as soft.
  • The FA values of fibroblastic meningiomas were significantly higher than those of meningothelial meningiomas (p = 0.002).
  • The FA values of hard tumors were significantly higher than those of soft tumors (p = 0.0003).
  • Logistic regression analysis demonstrated that the FA value was a significant independent predictor of tumor consistency (p = 0.007).
  • CONCLUSIONS: The FA value calculated from preoperative MR DT imaging predicts meningioma consistency.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17937223.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE: Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg; 2002 Aug;97(2):341-6
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
  • OBJECT: The management of certain meningiomas of the skull base and those involving the dural venous sinuses remains a challenge.
  • In recent reports it has been suggested that hydroxyurea chemotherapy can cause regression of unresectable and recurrent meningiomas.
  • The authors report their experience in using hydroxyurea for the treatment of patients with recurrent or unresectable meningiomas.
  • METHODS: Hydroxyurea was administered at a dosage of approximately 20 mg/kg/day to 11 women and nine men (median age 59 years, range 31-75 years) with recurrent or unresectable intracranial meningiomas (12 basal, two parasagittal, and six multiple).
  • In 16 patients the meningiomas were benign, in three they had atypical features, and in one the meningioma was malignant.
  • All patients had measurable residual disease.
  • Four patients with benign meningiomas had previously received radiotherapy (two were treated with conventional fractionated radiotherapy and two with stereotactic radiosurgery), three with atypical meningiomas received conventional fractionated radiotherapy, and the one with a malignant meningioma received conventional radiotherapy with additional stereotactic radiosurgery.
  • Tumor enlargement was documented in all patients on neuroimages obtained before initiation of hydroxyurea therapy.
  • All patients were evaluable for response to therapy.
  • In 12 patients with benign meningiomas, the disease had stabilized on neuroimages obtained posttreatment (median duration of treatment 122 weeks, range 8-151 weeks), and two of these showed clinical improvement.
  • One patient with a benign meningioma experienced a minor partial response that was noted after 39 weeks of treatment and was confirmed on neuroimaging and clinical evaluations.
  • In three others with benign meningiomas, progression was confirmed on neuroimages obtained after 41, 55, and 66 weeks, respectively: the 1-year freedom from progression rate was 0.93 (standard error 0.07) in patients with benign meningiomas.
  • In three patients with atypical meningiomas, the tumors had progressed on neuroimages obtained after 12, 19, and 45 weeks, respectively.
  • In the patient with a malignant meningioma, progression was confirmed on neuroimages obtained at 24 weeks.
  • Hydroxyurea has been reasonably well tolerated, although one patient discontinued therapy because of moderate myelosuppression.
  • CONCLUSIONS: Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Disease Progression. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / physiopathology. Meningioma / drug therapy. Meningioma / physiopathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / physiopathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Remission Induction. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12186462.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


27. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
  • OBJECT: The first aim of this study was to diagnose more aggressive and potentially recurrent meningiomas using an in vitro embryonic chick heart invasiveness assay in which lysosomal enzyme cathepsin B was used as the invasiveness marker.
  • The second aim was to confirm if cathepsin B and/or cathepsin L and their endogenous inhibitors were also prognostic parameters in the clinical study of 119 patients with meningioma.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • In vitro invasion assays of the malignant meningioma cells were used to assess the invasive potential related to the cysteine cathepsins.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • Univariate and multivariate analyses were used to compare these parameters with established biological markers of meningioma recurrence in 119 patients with meningiomas.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • More intensive staining of cathepsin B in these tumors was not only found at the tumor front, but also in the invading pseudopodia of a single migrating tumor cells.
  • Matrigel invasion of malignant meningioma cells was significantly altered by modulating cathepsin B activity and by stefin B silencing.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • As expected, WHO grade, age, and Simpson grade (complete tumor resection) were prognostic, with Simpson grade only relevant in the short term (up to 90 months) but not in longer-term follow-up.
  • CONCLUSIONS: The data indicate that the cysteine cathepsins and their inhibitors are involved in a process related to early meningioma recurrence, regardless of their histological classification.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cathepsin B / genetics. Cystatin A / genetics. Cystatin B / genetics. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neurosurgical Procedures. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747051.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CSTB protein, human; 0 / Cystatin A; 0 / Cysteine Proteinase Inhibitors; 88844-95-5 / Cystatin B; EC 3.4.22.1 / CTSB protein, human; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


28. Huang B, Lei T, Liu K, Zhang L, Li L, Zhang Z, Xue D: The regulatory effects of protein kinase C on the proliferation of cultured human low-passage meningioma cells. J Tongji Med Univ; 2000;20(3):217-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The regulatory effects of protein kinase C on the proliferation of cultured human low-passage meningioma cells.
  • The potential role of the protein kinase C (PKC)-mediated signal transduction pathways in growth regulation was evaluated and the effects and the possible mechanism of PKC inhibitor on low-passage human meningioma cells in vitro investigated.
  • Freshly resected meningiomas obtained from the operation were placed into cell cultures.
  • The numbers of the cultured meningioma cells were counted to evaluate the effect of the PKC inhibitor staurosporine on proliferation of meningioma cells.
  • The basal phosphatidylinositol (PI) turnover rate and the inhibitory rate of starosporine on the proliferation of the meningioma cells were detected.
  • It was found that the proliferation of the low-passage human meningioma cells was inhibited by staurosporine in a dose-dependent manner.
  • It was suggested that PKC-mediated signal pathway is involved in the proliferation of the low-passage human meningioma cells.
  • The procedure that PKC regulated the proliferation of human meningioma cells is a complex procedure.
  • It is necessary to make more research in order to explore a non-operation therapy or an adjuvant therapy.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Protein Kinase C / physiology
  • [MeSH-minor] Cell Division / drug effects. Humans. Signal Transduction. Staurosporine / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11215053.001).
  • [ISSN] 0257-716X
  • [Journal-full-title] Journal of Tongji Medical University = Tong ji yi ke da xue xue bao
  • [ISO-abbreviation] J. Tongji Med. Univ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.13 / Protein Kinase C; H88EPA0A3N / Staurosporine
  •  go-up   go-down


29. Ragel BT, Jensen RL, Couldwell WT: Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors. Neurosurg Focus; 2007;23(4):E7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors.
  • In this article the authors discuss the rationale and research supporting the hypothesis that meningioma tumorigenesis may, in part, be driven by overexpression of cyclooxygenase-2 (Cox-2) and that treatment with celecoxib, a selective Cox-2 inhibitor, may hold therapeutic promise.
  • Because therapies for recurrent or aggressive meningiomas (atypical or malignant subtypes) such as chemotherapy and radiotherapy generally offer little therapeutic benefit, interest in targeting Cox-2 has grown.
  • This rate-limiting enzyme of prostaglandin synthesis can be inhibited with nonsteroidal antiinflammatory drugs (NSAIDs) such as ibuprofen and celecoxib.
  • Treatment with NSAIDs has been shown to curb the tumorigenic properties of prostaglandins in several cancer models via both Cox-2-dependent and -independent mechanisms.
  • In addition, celecoxib is well tolerated in humans, making its use as a chronic therapy for meningiomas attractive.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Cyclooxygenase 2 / physiology. Cyclooxygenase 2 Inhibitors / therapeutic use. Meningeal Neoplasms / etiology. Meningioma / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961044.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 47
  •  go-up   go-down


30. Kunishio K, Kobayashi K, Kagawa M, Makabe T, Matsumoto A, Matsumoto Y: [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene]. Gan To Kagaku Ryoho; 2007 Feb;34(2):265-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].
  • We report a case with malignant meningioma in which new preliminary treatment trial was performed by chemotherapy using anti-cancer drugs selected on the basis of multidrug resistance gene mRNA expression, such as MDR1, MGMT, MRP1, MRP2, MXR1, and DNA topoisomerase II alpha, from RT-PCR assay.
  • A 43-year-old female had been operated for parasagittal anaplastic meningioma three times because of recurrences. partial removal of tumor was performed at the 3rd operation.
  • RT-PCR assay of this tissue revealed overexpression of MDR1, MRP1, MRP2 and MGMT mRNA, but no ABCG 2 expression was observed.
  • The patient was given mitoxantrone and hydroxyurea following irradiation, after which the tumor did not recur for three years.
  • Preliminary individual adjuvant chemotherapy based on mRNA expression of drug-resistance gene is available for the treatment of recurrent malignant meningioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. DNA Modification Methylases. DNA Repair Enzymes. Drug Administration Schedule. Female. Humans. Hydroxyurea / administration & dosage. Membrane Transport Proteins / biosynthesis. Mitoxantrone / administration & dosage. Multidrug Resistance-Associated Proteins / biosynthesis. P-Glycoprotein / biosynthesis. P-Glycoprotein / genetics. RNA, Messenger / biosynthesis. Tumor Suppressor Protein p14ARF / biosynthesis. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301541.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / multidrug resistance-associated protein 2; BZ114NVM5P / Mitoxantrone; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


31. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY: Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol; 2010 Jan;96(2):211-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
  • There are no established treatments for recurrent meningioma when surgical and radiation options are exhausted.
  • The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth.
  • In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients.
  • Patients with recurrent histologically confirmed meningiomas with no more than 2 previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and 8 (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 25%, 12-month PFS (PFS12) 13%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • For atypical and malignant tumors, PFS6 was 29%, PFS12 18%, OS6 71%, and OS12 65%.
  • There were no objective imaging responses, but 8 patients (32%) maintained stable disease.
  • Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma.
  • The role of EGFR inhibitors in meningiomas is unclear.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):45-51 [8583244.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1047-51 [17353924.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • (PMID = 19562255.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-06; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA062421-06; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01CA62405; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS511532; NLM/ PMC3786190
  •  go-up   go-down


32. Gupta V, Samuleson CG, Su S, Chen TC: Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. Neurosurg Focus; 2007;23(4):E9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.
  • Although most meningiomas are treated surgically, it may not be possible to completely remove atypical, malignant, and surgically inaccessible meningiomas; in the majority of these cases there is tumor recurrence.
  • The authors have already reported initial preclinical results on the efficacy of imatinib in the treatment of meningiomas; however, a recent Phase II trial of imatinib in patients with recurrent meningiomas did not demonstrate significant antitumor activity.
  • To enhance the activity of imatinib, the authors investigated the use of a combination therapy with nelfinavir on primary meningioma cells and meningioma cell lines IOMM-Lee and CH157.
  • In low-dose combination therapy with imatinib, nelfinavir potentiated the antiproliferative and anti-colony formation effects of imatinib.
  • Primary meningioma cells responded better to combination therapy than to imatinib alone.
  • Treatment induced a dose-dependent antiproliferative effect, decreased cell survival, and inhibited colony formation.
  • Western blotting demonstrated decreased levels of survivin protein on combination therapy.
  • Because meningiomas have very high levels of survivin protein, survivin inhibition by nelfinavir may represent a potential mechanism for the additive effect observed with imatinib.
  • The authors propose that nelfinavir not only potentiates imatinib efficacy, it also abrogates resistance to imatinib by decreasing survivin protein levels in meningiomas.
  • In an in vivo assay, this combination therapy was found to be more effective than imatinib alone.
  • More preclinical work with in vivo models is needed to determine if this new combination therapy will translate into a viable future therapy for meningiomas.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. HIV Protease Inhibitors / administration & dosage. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Nelfinavir / administration & dosage. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Animals. Benzamides. Cell Culture Techniques. Cell Line, Tumor. Drug Therapy, Combination. Humans. Imatinib Mesylate. Inhibitor of Apoptosis Proteins. Mice. Mice, Nude. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NELFINAVIR MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961046.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Benzamides; 0 / HIV Protease Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; HO3OGH5D7I / Nelfinavir
  •  go-up   go-down


33. Martin AJ, Hammond CJ, Dobbs HJ, Al-Sarraj S, Thomas NW: Spinal meningioma after treatment for Hodgkin disease. Case report. J Neurosurg; 2001 Oct;95(2 Suppl):232-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal meningioma after treatment for Hodgkin disease. Case report.
  • Long-term survivors of Hodgkin disease may develop second primary tumors caused by the mutagenic effects of radio- and chemotherapy.
  • The authors describe the case of a 35-year-old woman who presented with an unusual meningioma of the cervical spine 9 years after undergoing combined-modality treatment for Hodgkin disease.
  • To the authors' knowledge, this is the first report of spinal meningioma as a complication of such therapy.
  • Whereas radiation-induced intracranial meningiomas are well described in the literature, treatment-induced meningiomas of the spine have not been widely recognized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / therapy. Meningioma / etiology. Neoplasms, Second Primary. Spinal Neoplasms / etiology
  • [MeSH-minor] Adult. Combined Modality Therapy / adverse effects. Female. Humans. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11599842.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Chamberlain MC, Glantz MJ, Fadul CE: Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology; 2007 Sep 4;69(10):969-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
  • BACKGROUND: Somatostatin receptors, especially the sst2A subtype, are present on most meningiomas.
  • The addition of somatostatin inhibits meningioma growth in vitro in some studies.
  • There have been anecdotal reports of octreotide inhibiting growth in meningiomas.
  • OBJECTIVES: A prospective pilot trial of sustained-release somatostatin (Sandostatin LAR) in 16 patients with recurrent meningiomas was conducted with a primary study objective of progression-free survival at 6 months.
  • METHODS: Sixteen patients (11 women, 5 men; median age 58) with recurrent meningioma were treated prospectively with long-acting somatostatin.
  • Patients had progressed radiographically after prior therapy with surgery (14/16; complete resection in 5; subtotal in 7; biopsy only in 2), radiotherapy (13/16), and chemotherapy (12/16).
  • All patients had confirmation of the presence of somatostatin receptors in their tumor using (111)In-octreotide, a long-acting somatostatin agonist, SPECT scanning.
  • Five [corrected] partial responses, five stable disease, and six [corrected] progressive disease patterns were seen.
  • CONCLUSIONS: In this small trial of patients with recurrent meningiomas shown to overexpress somatostatin receptors by octreotide scintigraphy, long-acting somatostatin (Sandostatin LAR) was administered on a monthly schedule.
  • Toxicity was minimal, suggesting somatostatin analogues may offer a novel, relatively nontoxic alternative treatment for recurrent meningiomas.
  • [MeSH-major] Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods. Somatostatin / administration & dosage. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Delayed-Action Preparations. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Pilot Projects. Prospective Studies

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Neurology. 2008 Jan 22;70(4):325
  • (PMID = 17785665.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 51110-01-1 / Somatostatin
  •  go-up   go-down


35. Ware ML, Larson DA, Sneed PK, Wara WW, McDermott MW: Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma. Neurosurgery; 2004 Jan;54(1):55-63; discussion 63-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma.
  • OBJECTIVE: Recurrent atypical and malignant meningiomas are difficult to treat successfully.
  • Chemotherapy to date has been unsuccessful, and radiosurgery is limited to smaller tumors.
  • Reoperation alone provides limited tumor control and limited prolonged survival.
  • The addition of brachytherapy at the time of operation is an option.
  • Here, we report the results of our series of patients with recurrent malignant meningioma treated with resection and brachytherapy with permanent low-dose (125)I.
  • METHODS: The charts of patients in our database with recurrent atypical and malignant meningiomas treated by surgical resection and permanent (125)I brachytherapy at the University of California, San Francisco, between 1988 and 2002 were selected for this study.
  • Calculations of disease-free survival and overall survival curves were made by the Kaplan-Meier actuarial method.
  • Univariate analysis between Kaplan-Meier curves was based on the log-rank statistic, with a significance level set at a value of P </= 0.05.
  • RESULTS: Seventeen patients had recurrent malignant meningioma, and four had recurrent atypical meningioma.
  • The median number of sources implanted after surgical resection was 30 (range, 4-112 sources), with a median total activity of 20 mCi (range, 3.3-85.9 mCi).
  • The median time to progression after brachytherapy was 11.6 months for patients with malignant meningioma and 10.4 months for the combined group.
  • There was a trend toward longer disease-free survival time in patients after gross total resection versus subtotal resection and in patients with tumors located at the convexity and parasagittally versus at the cranial base.
  • The median overall survival after diagnosis was 9.4 years for patients with atypical meningioma, 6.6 years for those with malignant meningioma, and 8.0 years for all patients combined.
  • Survival from the time of resection and implantation of (125)I was 1.6 years for patients with atypical meningioma, 2.4 years for patients with malignant meningioma, and 2.4 years for the combined group.
  • CONCLUSION: The options for patients with recurrent atypical or malignant meningiomas are limited.
  • Our results suggest that for tumors not suitable for radiosurgery, resection followed by permanent brachytherapy should be considered as a potential salvage treatment.
  • However, this approach results in a relatively high complication rate in these heavily treated patients and requires meticulous surgical technique and medical therapies to assist with wound healing after surgery.
  • [MeSH-major] Brachytherapy. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14683541.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Sessums K, Mariani C: Intracranial meningioma in dogs and cats: a comparative review. Compend Contin Educ Vet; 2009 Jul;31(7):330-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma in dogs and cats: a comparative review.
  • Meningiomas are extraaxial tumors that arise from the arachnoid layer of the meninges.
  • Meningiomas in both species grow slowly and have an insidious onset of clinical signs.
  • These tumors are more likely to be malignant in dogs.
  • Surgery, radiation, and chemotherapy can target the primary tumor, whereas steroids and anticonvulsants are confined to treating secondary effects of the tumor.
  • Surgery is the preferred primary option for cats because the tumor can be excised completely in most cases.
  • If the meningioma cannot be resected in its entirety, radiation therapy can increase survival time.
  • [MeSH-major] Cat Diseases / diagnosis. Dog Diseases / diagnosis. Meningeal Neoplasms / veterinary. Meningioma / veterinary
  • [MeSH-minor] Animals. Breeding. Cats. Dogs. Prognosis. Risk Factors. Species Specificity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19746352.001).
  • [ISSN] 1940-8315
  • [Journal-full-title] Compendium (Yardley, PA)
  • [ISO-abbreviation] Compend Contin Educ Vet
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


37. Ragel BT, Gillespie DL, Kushnir V, Polevaya N, Kelly D, Jensen RL: Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro. Neurosurgery; 2006 Nov;59(5):1109-20; discussion 1120-1
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
  • OBJECTIVE: Although the chemotherapy drug hydroxyurea (HU) and the antiprogesterone mifepristone (RU486) have been used to treat meningiomas for which surgical and radiation therapies have failed, results have been disappointing.
  • The addition of calcium channel antagonists (CCAs) to chemotherapeutic drugs enhances tumor growth inhibition in other tumor types, and the authors demonstrated that CCAs can block meningioma growth in vitro and in vivo.
  • The purpose of this study was to test the effects of the addition of a CCA to HU or RU486 on meningioma growth.
  • METHODS: Primary and malignant (IOMM-Lee) meningioma cell lines were treated with HU, RU486, or either of these plus diltiazem or verapamil.
  • Similar cell lines were implanted into nude mice and were treated with HU or RU486, in combination with a CCA.
  • Tumors were analyzed by light microscopy, MIB-1, and factor VIII immunohistochemical staining studies.
  • RESULTS: The addition of diltiazem or verapamil to HU or RU486 augmented meningioma growth inhibition by 20 to 60% in vitro.
  • In vivo, tumors treated with combination drugs were smaller; and immunohistochemical analysis of the IOMM-Lee tumors showed a 10% decrease in the MIB-1 ratio (from 0.41 to 0.30) and an approximate 75% decrease in microvascular density.
  • CONCLUSION: The addition of diltiazem or verapamil to HU or RU486 augments meningioma growth inhibition in vitro by inducing apoptosis and G1 cell-cycle arrest.
  • The combination of HU and diltiazem inhibited the growth of meningiomas in vivo by decreasing proliferation and microvascular density.
  • These results suggest a possible role for these drugs as an additional adjuvant therapy for recurrent or unresectable meningiomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Apoptosis / drug effects. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / physiopathology. Meningioma / drug therapy. Meningioma / physiopathology
  • [MeSH-minor] Aged. Animals. Antineoplastic Agents / administration & dosage. Calcium Channel Blockers / administration & dosage. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Female. Humans. Hydroxyurea / administration & dosage. Male. Mice. Mice, Nude. Middle Aged. Mifepristone / administration & dosage. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143245.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Calcium Channel Blockers; 320T6RNW1F / Mifepristone; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


38. Lee EJ, Chang CH, Wang LC, Hung YC, Chen HH: Two primary brain tumors, meningioma and glioblastoma multiforme, in opposite hemispheres of the same patient. J Clin Neurosci; 2002 Sep;9(5):589-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two primary brain tumors, meningioma and glioblastoma multiforme, in opposite hemispheres of the same patient.
  • We report a case with double primary intracranial tumors of different cell types without phacomatosis.
  • Initial computed tomographic (CT) examinations revealed a large hyperdense tumor over the right frontal lobe, suggestive of an extra-axial meningioma.
  • Additionally, there was unusual brain edema in the contralateral hemisphere that subsequently proved to originate from an intrinsic tumor.
  • Pathological examinations confirmed the two tumors to be a meningioma and a glioblastoma multiforme, respectively.
  • The patient made an uneventful recovery after treatment.
  • Although meningioma and glioma represent two common primary intracranial tumors, the simultaneous development of the two tumors is rare.
  • We suggest that extraordinary brain edema far remote from the primary brain lesion warrants special attention for identifying other potentially undetected lesions.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Meningioma / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Female. Functional Laterality / physiology. Humans. Neoplasm Recurrence, Local. Seizures / drug therapy. Seizures / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12383424.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


39. Picquet J, Valo I, Jousset Y, Enon B: Primary pulmonary meningioma first suspected of being a lung metastasis. Ann Thorac Surg; 2005 Apr;79(4):1407-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary meningioma first suspected of being a lung metastasis.
  • Primary extracranial and extraspinal meningiomas are rare tumors.
  • We describe a primary pulmonary meningioma first suspected of being a metastasis because it presented as a solitary subpleural pulmonary nodule in a patient with breast cancer.
  • The absence of radiographic change after 6 months of chemotherapy led to resection of the breast and lung lesions.
  • A complete central nervous system evaluation eliminated other locations of meningioma, allowing the diagnosis of primary pulmonary meningioma.
  • [MeSH-major] Lung Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797095.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Matsuda R, Nikaido Y, Yamada T, Mishima H, Tamaki R: [High-dose radiation-induced meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia]. No Shinkei Geka; 2005 Mar;33(3):277-80
Genetic Alliance. consumer health - Radiation induced meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose radiation-induced meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia].
  • Computed tomography demonstrated two, enhancing bilateral sided intracranial tumors.
  • After surgery, this patient presented meningiomas which histologically, were of the meningothelial type.
  • The high cure rate in childhood ALL, attributable to aggressive chemotherapy and prophylatic cranial irradiation, is capable of inducing secondary brain tumor.
  • Twelve cases of high-dose radiation-induced meningioma following ALL are also reviewed.
  • [MeSH-major] Cranial Irradiation / adverse effects. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773318.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


41. Regel JP, Schoch B, Sandalcioglu IE, Wieland R, Westermeier C, Stolke D, Wiedemayer H: Malignant meningioma as a second malignancy after therapy for acute lymphatic leukemia without cranial radiation. Childs Nerv Syst; 2006 Feb;22(2):172-5
MedlinePlus Health Information. consumer health - Drug Reactions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma as a second malignancy after therapy for acute lymphatic leukemia without cranial radiation.
  • RATIONALE: Meningiomas in the pediatric age group are very rare tumors, comprising about 1-4.2% of all primary pediatric intracranial tumors.
  • CASE REPORT: We present a 17-year-old patient who suffered from an intraventricular malignant meningioma.
  • At the age of 2 years, acute lymphatic leukemia (common ALL [cALL]) was diagnosed and successfully treated with chemotherapy.
  • There was no cranial radiation therapy.
  • In December 2001, 13 years after diagnosis of cALL, he complained of headache, vomiting, and walking difficulties.
  • The tumor was removed completely.
  • Histological diagnosis revealed a malignant papillary meningioma.
  • After removal of a recurrent meningioma 16 months later, he received local radiotherapy.
  • CONCLUSION: Pathogenetic mechanisms, treatment options, and prognosis of meningiomas and secondary malignancies of this age group are discussed.
  • [MeSH-major] Drug-Related Side Effects and Adverse Reactions. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Drug Therapy / methods. Humans. Magnetic Resonance Imaging / methods. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Dec 15;95(12):2562-70 [12467071.001]
  • [Cites] Pediatr Neurosurg. 2001 May;34(5):264-7 [11423779.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Aug;36(8):598-601 [8831206.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):406-16 [10958549.001]
  • [Cites] Childs Nerv Syst. 2001 Nov;17 (11):656-62 [11734983.001]
  • [Cites] Med Phys. 2001 Nov;28(11):2387-8 [11764047.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:247-54 [3628810.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):964-9 [11420471.001]
  • (PMID = 16456690.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Raza SM, Anderson WS, Eberhart CG, Wolinsky JP, Gokaslan ZL: The application of surgical cordectomy in the management of an intramedullary-extramedullary atypical meningioma: case report and literature review. J Spinal Disord Tech; 2005 Oct;18(5):449-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The application of surgical cordectomy in the management of an intramedullary-extramedullary atypical meningioma: case report and literature review.
  • BACKGROUND: The English literature describes only four cases of intraspinal tumors requiring surgical intervention in the form of cordectomy; none of these cases was for meningiomas.
  • Intraspinal meningiomas, typically extramedullary-intradural, require treatment in the form of resection with dural margin excision.
  • The presentation of an intramedullary atypical World Health Organization grade II meningioma is rare.
  • The authors report a case of a transformed intramedullary-extramedullary atypical meningioma treated with cordectomy.
  • METHODS: The patient was a 65-year-old woman who presented with a recurrent thoracic meningioma status post three attempted resections, radiation therapy, and a trial of hydroxyurea chemotherapy.
  • Extension of abnormal T2 signal within the cord superiorly to C7 was noted with a 1-cm enhancing extra-axial lesion at T10 and an extradural mass posteriorly T12 also noted.
  • The patient underwent a T2-T7 laminectomy with a T2-T8 cordectomy.
  • CONCLUSIONS: This case highlights the viability of surgical cordectomy in the treatment of varying intramedullary processes under appropriate indications.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Spinal Cord / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189459.001).
  • [ISSN] 1536-0652
  • [Journal-full-title] Journal of spinal disorders & techniques
  • [ISO-abbreviation] J Spinal Disord Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


43. Gonçalves AM, Page P, Domigo V, Méder JF, Oppenheim C: Abrupt regression of a meningioma after discontinuation of cyproterone treatment. AJNR Am J Neuroradiol; 2010 Sep;31(8):1504-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abrupt regression of a meningioma after discontinuation of cyproterone treatment.
  • The multiplicity of meningiomas or abrupt lesion growth in patients treated with cyproterone acetate suggests that this progestative treatment may promote lesion growth.
  • We report the rapid regression of an incidental meningioma after discontinuation of a 10-year cyproterone acetate treatment.
  • This unique observation suggests that conservative management of meningiomas may be the best option among users of high doses of cyproterone acetate, given that spontaneous regression may occur after hormonal treatment discontinuation.
  • [MeSH-major] Alopecia / drug therapy. Androgen Antagonists / adverse effects. Cyproterone / adverse effects. Meningeal Neoplasms / chemically induced. Meningioma / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20053802.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; E61Q31EK2F / Cyproterone
  •  go-up   go-down


44. Jung DI, Kim HJ, Park C, Kim JW, Kang BT, Lim CY, Park EH, Sur JH, Seo MH, Hahm DH, Park HM: Long-term chemotherapy with lomustine of intracranial meningioma occurring in a miniature schnauzer. J Vet Med Sci; 2006 Apr;68(4):383-6
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term chemotherapy with lomustine of intracranial meningioma occurring in a miniature schnauzer.
  • A mass in the diencephalon was noted on brain magnetic resonance images.
  • Based on diagnostic image analysis, this lesion strongly suggested meningioma.
  • The patient's symptoms were well controlled by a combination therapy of prednisolone and lomustine (CCNU), and survived for thirteen months after diagnosis.
  • This case was diagnosed as a meningioma based on histopathological findings.
  • This report describes the clinical findings, imaging characteristics, and pathologic features of a diencephalic and mesencephalic meningioma and long-term survival after lomustine and prednisolone therapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679732.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 7BRF0Z81KG / Lomustine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


45. Kumpulainen EJ, Hirvikoski PP, Johansson RT: Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer. Acta Oncol; 2008;47(1):120-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
  • The aim of the study is to report the long-term outcome and secondary tumours of early breast cancer patients of adjuvant CNF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) chemotherapy.
  • The therapies included surgery, radiation therapy, adjuvant CNF chemotherapy, and tamoxifen according to hormonal status.
  • The median follow-up time was 12.9 years.
  • Two cases of leukemia, six cases of skin cancer, two cases of Hodgkin's disease, two cases of meningioma, and two cases of endometrial cancer were observed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Disease-Free Survival. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Methotrexate / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097780.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


46. Karadereler S, Aker F, Berkman Z: Intraparenchymal meningioma in a child. Case report and review of the literature. J Neurosurg; 2004 Aug;101(1 Suppl):112-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraparenchymal meningioma in a child. Case report and review of the literature.
  • The authors reported a rare case of temporal intraparenchymal meningioma without dural attachment.
  • A 14-year-old boy presented with a 4-month history of generalized tonic-clonic seizures.
  • Neurological examination showed no abnormality.
  • The tumor was hypointense on T1-weighted and hyperintense on T2-weighted MR images, and enhanced heterogeneously after Gd-diethylenetriamine pentaacetic acid administration.
  • Gross-total excision of the tumor was accomplished.
  • Histopathological examinations indicated that the lesion was a meningioma.
  • Magnetic resonance images revealed no residual tumor during a 3-year follow-up period.
  • In this report, the authors review the literature and discuss intraparenchymal meningiomas in the differential diagnosis of intraaxial lesions.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Temporal Lobe / pathology
  • [MeSH-minor] Adolescent. Brain Edema / drug therapy. Epilepsy, Tonic-Clonic / etiology. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206982.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Tournat H, Huchet A, Ouhabrache N, Thomas IC, Roubaud G, Maire JP: [Bone metastatic evolution of a recurrent meningioma: case report]. Cancer Radiother; 2006 Dec;10(8):590-4
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone metastatic evolution of a recurrent meningioma: case report].
  • We report the case of a 57-year-old man who presented with two local recurrences and metastatic dissemination of a papillary meningioma of the sphenoid 3 years after surgery.
  • Treatment consisted in a combination of surgery for the local recurrence in the initial site, radiotherapy and chemotherapy for bone metastases.
  • Evolution of the disease spread over 7.5 years.
  • The literature relating metastatic meningiomas is reviewed; prognostic factors and main therapeutic protocols are discussed.
  • [MeSH-major] Bone Neoplasms / secondary. Bone Neoplasms / therapy. Meningeal Neoplasms. Meningioma. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Time Factors

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876455.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


48. Shimizu J, Matsumoto M, Yamazaki E, Yasue M: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo); 2008 May;48(5):227-30
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration.
  • An 80-year-old male visited the hospital as an outpatient with a head injury sustained in a traffic accident.
  • Brain computed tomography incidentally revealed a left frontal lobe tumor measuring 5 cm in a diameter.
  • The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy.
  • The tumor was seen as an isointense lesion on T(1)-weighted magnetic resonance (MR) images with enhancement by gadolinium, and as a heterogeneously hyperintense mass on T(2)-weighted MR images.
  • The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane.
  • The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation.
  • Computed tomography and MR imaging performed at this time revealed remarkable regression of the tumor.
  • The signal intensity change with regression of the tumor on T(2)-weighted images was observed as a hypointense lesion.
  • Thus, we wish to emphasize that treatment of meningiomas, especially those diagnosed incidentally, must be based on a thorough consideration of any history of hormonal therapy with prostate disease.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Chlormadinone Acetate / administration & dosage. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Regression, Spontaneous
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Progesterone / agonists. Prostatic Hyperplasia / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0SY050L61N / Chlormadinone Acetate; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


49. Brassesco MS, Valera ET, Neder L, Castro-Gamero AM, de Oliveira FM, Santos AC, Scrideli CA, Oliveira RS, Machado HR, Tone LG: Childhood radiation-associated atypical meningioma with novel complex rearrangements involving chromosomes 1 and 12. Neuropathology; 2009 Oct;29(5):585-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood radiation-associated atypical meningioma with novel complex rearrangements involving chromosomes 1 and 12.
  • Meningiomas are recognized as the most common late complication following radiotherapy.
  • However, cytogenetic studies in childhood atypical radiation-induced meningioma are sporadic, mainly because this condition generally occurs after a long latent period.
  • In the present study we show the results of conventional and molecular cytogenetics in a 14-year-old boy with a secondary atypical meningioma.
  • Previous cytogenetic studies on adult spontaneous and radiation-associated meningiomas showed loss of chromosome 22 as the most frequent change, followed by loss of the short arm of chromosome 1.
  • To the best of our knowledge this is the first report of highly complex chromosome aberrations in the pediatric setting of meningioma.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Meningioma / genetics. Neoplasms, Radiation-Induced / genetics. Neoplasms, Second Primary / genetics
  • [MeSH-minor] Adolescent. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 6 / genetics. Combined Modality Therapy. Comparative Genomic Hybridization. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Medulloblastoma / drug therapy. Medulloblastoma / pathology. Medulloblastoma / radiotherapy

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077038.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


50. Sioka C, Kyritsis AP: Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol; 2009 Mar;92(1):1-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
  • Meningioma is a common intracranial tumor, originating from the meninges of the skull or spinal canal.
  • Most meningiomas are benign tumors, however atypical or anaplastic tumors can be found in 6% of cases.
  • Patients with asymptomatic small benign meningiomas can be followed without therapy, but in symptomatic patients complete surgical resection should be performed.
  • For recurrent previously resected tumors re-resection is recommended followed by radiotherapy in selected cases.
  • Antiprogesterone treatment can also be considered in recurrent benign meningiomas.
  • Immunotherapy with interferon-alpha and chemotherapy should be reserved for all cases of recurrent meningiomas (benign, atypical, and malignant) when all the standard therapies have failed or contraindicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunotherapy / methods. Meningeal Neoplasms / therapy. Meningioma / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Clinical Trials as Topic. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Jun;68(2):131-40 [15218949.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):543-7 [1346787.001]
  • [Cites] Rev Neurol. 1997 Dec;25(148):2002-5 [9528047.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1865-74 [10815909.001]
  • [Cites] Eur J Cancer. 1991;27(11):1453-7 [1660295.001]
  • [Cites] J Clin Neurosci. 2008 Jun;15(6):721-2; author reply 722-3 [18406141.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):365-73; discussion 373-4 [7731518.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E10 [17961034.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):133-42 [11995814.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Feb;34(2):265-8 [17301541.001]
  • [Cites] Neurochirurgie. 2004 Sep;50(4):461-7 [15547484.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1427-30 [15690330.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):1109-20; discussion 1120-1 [17143245.001]
  • [Cites] Eur J Cancer. 1991;27(4):416-9 [1828169.001]
  • [Cites] Skull Base. 2006 Aug;16(3):157-60 [17268588.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):132-5 [10883917.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Cancer Invest. 2006 Dec;24(8):727-33 [17162554.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Hum Reprod. 1994 Jun;9 Suppl 1:202-7 [7962466.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Jul;110(7):645-8 [18471956.001]
  • [Cites] Acta Neurol Scand. 1987 Jun;75(6):434-6 [2888257.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):187-92 [17525632.001]
  • [Cites] Lancet. 1995 Feb 4;345(8945):331 [7837901.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):692-702; discussion 702-3 [10719866.001]
  • (PMID = 19023520.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 43
  •  go-up   go-down


51. Di Patre PL, Radziszewski W, Martin NA, Brooks A, Vinters HV: A meningioma-mimicking tumor caused by Mycobacterium avium complex in an immunocompromised patient. Am J Surg Pathol; 2000 Jan;24(1):136-9
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meningioma-mimicking tumor caused by Mycobacterium avium complex in an immunocompromised patient.
  • Intracranial tuberculomas manifesting radiologically as typical dural-based "meningiomas" have been reported, most frequently in immunosuppressed patients.
  • According to published reports, intracranial tuberculomas are always due to infection by Mycobacterium tuberculosis.
  • We report a case of a 50-year-old woman with systemic lupus erythematosus (SLE) who presented with a dural based, meningioma-like mass in the right frontal region, resulting from a localized infection by Mycobacterium avium complex.
  • Histologically, the mass resembled a meningioma in being composed of spindly cells arranged in a fascicular pattern.
  • Immunohistochemical stains showed this tumor to consist of a large aggregate of AFB-laden histiocytes without caseating necrosis or multinucleated giant cells.
  • [MeSH-major] Immunocompromised Host. Mycobacterium avium-intracellulare Infection / diagnosis. Tuberculoma, Intracranial / diagnosis
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Azathioprine / therapeutic use. Female. Humans. Immunohistochemistry. Immunosuppressive Agents / therapeutic use. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Middle Aged. Prednisone / therapeutic use. Tomography, X-Ray Computed


52. Cramer P, Thomale UW, Okuducu AF, Lemke AJ, Stockhammer F, Woiciechowsky C: An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report. J Neurosurg Spine; 2005 Aug;3(2):153-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report.
  • The authors report the case of a 23-year-old man who presented with a C1-3 spinal mass.
  • Following intraspinal decompression the tumor was histologically classified as an atypical meningioma (World Health Organization grade II).
  • Two further surgical interventions resulted in almost total removal of the meningioma.
  • During the 1.5-year follow-up period the diagnostic examinations identified a local tumor recurrence, an intraspinal C-6 metastasis, and a segmental instability with anterior C2-3 slippage and C3-4 kyphosis.
  • The tumor was resected and occipitocervical stabilization was performed.
  • Despite additional hydroxyurea-based chemotherapy, the patient presented 4 months later with a hemiparesis and a massive recurrence of the tumor mass involving the posterior fossa and the upper thoracic spine.
  • The authors discuss more aggressive therapeutic options in addition to surgery in patients with metastatic atypical meningiomas.
  • The results in the reported case indicate that meningiomas associated with cerebrospinal fluid metastasis may represent a higher grade of malignancy.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cervical Vertebrae. Decompression, Surgical. Disease Progression. Fatal Outcome. Humans. Hydroxyurea / therapeutic use. Joint Instability / etiology. Magnetic Resonance Imaging. Male. Myelography. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neurosurgical Procedures / adverse effects. Radiotherapy, Adjuvant. Reoperation. Spinal Diseases / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16370305.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


53. Mizutani J, Fukuoka M, Tsubouchi S, Otsuka T, Tono Y, Shimizu S, Matsui N: A rare case of lumbosacral meningioma: nondural attachment and possible enlargement by orally administered sex steroid. Spine (Phila Pa 1976); 2002 Aug 15;27(16):E377-81
Hazardous Substances Data Bank. MESTRANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of lumbosacral meningioma: nondural attachment and possible enlargement by orally administered sex steroid.
  • OBJECTIVES: To present a very rare case of orally ingested sex hormone pills inducing nondurally attached meningioma in the lumbosacral region.
  • SUMMARY OF BACKGROUND DATA: Meningiomas are known to enlarge in response to female sex hormones.
  • At this writing, few cases of nondurally based intradural meningioma have been reported.
  • Moreover, meningiomas in the lumbosacral region are very rare.
  • Spinal meningiomas predominantly arise in the fourth to sixth decades of life and are more common in women.
  • She had undergone oral sex steroid therapy for long-term oligomenorrhea.
  • Radiography disclosed a lumbosacral intradural tumor.
  • RESULTS: Complete removal of the tumor was performed.
  • The tumor was not adherent to the dura, and its appearance was that of a typical neurilemmoma.
  • However, the pathologic diagnosis was meningioma.
  • CONCLUSIONS: The tumor in the reported case may have enlarged in response to orally ingested sex steroid pills.
  • Nondural attachment intradural meningiomas are quite uncommon.
  • The gross appearance of the tumor during surgery was typical of neurilemmoma.
  • All the cases reported so far, including the current case, have involved tumor located in the lumbosacral region.
  • Care must be taken in the management of lumbosacral intradural tumors because tumors resembling neurilemmoma may in fact represent meningioma, some subtypes of which possess a high rate of recurrence.
  • [MeSH-major] Dura Mater / pathology. Gonadal Steroid Hormones / adverse effects. Meningioma / chemically induced. Meningioma / diagnosis. Spinal Cord Neoplasms / chemically induced. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Administration, Oral. Adult. Cauda Equina / pathology. Cauda Equina / radiography. Cauda Equina / surgery. Chlormadinone Acetate / administration & dosage. Chlormadinone Acetate / adverse effects. Diagnosis, Differential. Female. Humans. Hypesthesia / etiology. Low Back Pain / etiology. Lumbosacral Region. Magnetic Resonance Imaging. Mestranol / administration & dosage. Mestranol / adverse effects. Myelography. Neurilemmoma / diagnosis. Oligomenorrhea / drug therapy. Spine / pathology. Spine / radiography. Spine / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12195080.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0SY050L61N / Chlormadinone Acetate; B2V233XGE7 / Mestranol
  •  go-up   go-down


54. Epstein NE, Drexler S, Schneider J: Clear cell meningioma of the cauda equina in an adult: case report and literature review. J Spinal Disord Tech; 2005 Dec;18(6):539-43
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma of the cauda equina in an adult: case report and literature review.
  • In the pediatric population, clear cell meningiomas are more frequently intracranial than intraspinal in location.
  • Tumors recur in up to 40% of cases within 15 postoperative months and are often managed with repeated resection with or without radiation therapy.
  • The management strategy for adults with clear cell meningiomas involving the lumbar spinal canal (cauda equina) is less clearly defined.
  • Preoperative noncontrast MR studies of the brain and cervical and thoracic spine were negative.
  • Frozen-section diagnosis confirmed clear cell tumor.
  • Differential diagnoses included meningioma versus renal cell carcinoma.
  • Negative postoperative chest, abdominal, and pelvic computed tomography studies ruled out tumor of renal cell origin.
  • Consultations with multiple oncologists and radiation therapists recommended neither radiation nor chemotherapy following this initial surgery.
  • She remains disease-free 1 year postoperatively.
  • The high recurrence rate for clear cell meningiomas in children requires repeated tumor resection with or without secondary radiation therapy.
  • Following gross total resection of lumbar tumors in adults, reserving radiation therapy for secondary recurrences provides optimal management.
  • [MeSH-major] Cauda Equina / pathology. Cauda Equina / surgery. Meningioma / diagnosis. Meningioma / surgery. Peripheral Nervous System Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Paresis / diagnosis. Paresis / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16306847.001).
  • [ISSN] 1536-0652
  • [Journal-full-title] Journal of spinal disorders & techniques
  • [ISO-abbreviation] J Spinal Disord Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


55. Elder JB, Atkinson R, Zee CS, Chen TC: Primary intraosseous meningioma. Neurosurg Focus; 2007;23(4):E13
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intraosseous meningioma.
  • Primary intraosseous meningiomas are a subtype of primary extradural meningiomas and constitute fewer than 2% of meningiomas overall, but they represent approximately two thirds of all extradural meningiomas.
  • These types of meningiomas originate within the bones of the skull and thus can have a clinical presentation and radiographic differential diagnosis that is different from those for intradural meningiomas.
  • Primary intraosseous meningiomas are classified based on their location and histopathological characteristics.
  • Treatment primarily involves resection with wide margins if possible.
  • Very little literature exists regarding the use of adjuvant therapies such as radiation and chemotherapy for these tumors.
  • In fact, the literature regarding primary intra-osseous meningiomas consists mostly of clinical case reports and case series.
  • [MeSH-major] Meningioma / diagnosis. Meningioma / therapy. Skull Neoplasms / diagnosis. Skull Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961037.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


56. Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS: Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. J Neurooncol; 2002 Jan;56(2):133-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.
  • In this study, we evaluated lovastatin effects on meningioma cell proliferation and activation of the MEK-1-MAPK/ERK pathway.
  • The effect of lovastatin on cell proliferation was assessed in eight human meningioma cell cultures stimulated by platelet derived growth factor (PDGF)-BB, cerebrospinal fluid (CSF), and fetal bovine serum (FBS).
  • Concomitant with its growth inhibitory effects, lovastatin reduced phosphorylation/activation of MEK-1/2 in five meningiomas and MAPK/ERK in seven.
  • Lovastatin is a potent inhibitor of meningioma cell proliferation which may act in part by reducing activation of MEK-1-MAPK/ERK pathway.
  • Additional studies are warranted to assess whether lovastatin and similar HMG-CoA reductase inhibitors represent a new adjunctive chemotherapy for recurrent meningiomas.
  • [MeSH-major] Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Lovastatin / pharmacology. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / metabolism. Meningioma / drug therapy. Meningioma / metabolism
  • [MeSH-minor] Aged. Cell Division / drug effects. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Female. Humans. MAP Kinase Kinase 1. Male. Mevalonic Acid / pharmacology. Middle Aged. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MEVALONIC ACID .
  • Hazardous Substances Data Bank. LOVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Mar 30;199(3):1209-15 [8147861.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2604-7 [2183929.001]
  • [Cites] Cell Death Differ. 1999 Feb;6(2):99-104 [10200555.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):1071-9 [10071302.001]
  • [Cites] Am J Clin Oncol. 1998 Dec;21(6):579-83 [9856659.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):5889-92 [8392180.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Dec 30;205(3):1681-7 [7811252.001]
  • [Cites] Anticancer Res. 1992 Mar-Apr;12(2):317-24 [1580550.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Biochem J. 1999 Jan 15;337 ( Pt 2):171-7 [9882612.001]
  • [Cites] J Neurochem. 1996 Feb;66(2):710-6 [8592143.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7797-802 [10393901.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):233-9 [9258815.001]
  • [Cites] EMBO J. 2000 Oct 16;19(20):5418-28 [11032809.001]
  • [Cites] Cancer Biother Radiopharm. 1998 Oct;13(5):387-93 [10851430.001]
  • [Cites] J Biol Chem. 1993 Apr 15;268(11):7617-20 [8463291.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):633-42 [1325741.001]
  • [Cites] J Biol Chem. 1980 Jun 10;255(11):5134-40 [6768732.001]
  • [Cites] J Biol Chem. 1994 Dec 30;269(52):32848-57 [7806510.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4141-7 [9307305.001]
  • [Cites] J Neurooncol. 1999 Mar;42(1):1-11 [10360474.001]
  • [Cites] Clin Exp Metastasis. 1998 Oct;16(7):587-94 [9932605.001]
  • [Cites] J Neurochem. 1983 Feb;40(2):530-7 [6822836.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):34-41 [10739649.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2761-71 [10953355.001]
  • [Cites] Science. 1999 Nov 12;286(5443):1358-62 [10558990.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1616-22 [9603146.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Pathol. 1999 Jan;187(1):138-46 [10341714.001]
  • [Cites] J Neurochem. 1998 Jun;70(6):2397-405 [9603204.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3631-52 [10550163.001]
  • [Cites] Gastroenterology. 1992 Sep;103(3):982-9 [1499946.001]
  • (PMID = 11995814.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 9LHU78OQFD / Lovastatin; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1; EC 2.7.12.2 / MAP2K1 protein, human; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; S5UOB36OCZ / Mevalonic Acid
  •  go-up   go-down


57. Smith ER, Ott M, Wain J, Louis DN, Chiocca EA: Massive growth of a meningioma into the brachial plexus and thoracic cavity after intraspinal and supraclavicular resection. Case report and review of the literature. J Neurosurg; 2002 Jan;96(1 Suppl):107-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive growth of a meningioma into the brachial plexus and thoracic cavity after intraspinal and supraclavicular resection. Case report and review of the literature.
  • Extracranial meningiomas comprise approximately 2% of all meningiomas.
  • Involvement of peripheral nerves by meningioma, either by a primary tumor or through secondary extension of an intraaxial lesion, is a much rarer entity; there have been only two reported primary brachial plexus meningiomas and one description of secondary involvement of the brachial plexus by extension of an intraaxial lesion.
  • Although thoracic cavity meningiomas have been described in the literature, their pathogenesis is poorly understood.
  • The authors present the case report of a 36-year-old man who was initially treated for a thoracic spinal meningioma that infiltrated the brachial plexus.
  • After resection, progressive and massive growth with infiltration of the brachial plexus and pleural cavity occurred over a 5-year period despite radio- and chemotherapy.
  • [MeSH-major] Brachial Plexus Neuropathies / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Peripheral Nervous System Neoplasms / surgery. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adult. Decompression, Surgical. Fatal Outcome. Follow-Up Studies. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Reoperation. Thoracic Vertebrae / pathology. Thoracic Vertebrae / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11795697.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Benedetto N, Perrini P, Scollato A, Buccoliero AM, Di Lorenzo N: Intracranial meningioma containing metastatic colon carcinoma. Acta Neurochir (Wien); 2007 Aug;149(8):799-803; discussion 803
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma containing metastatic colon carcinoma.
  • Meningioma is the most common intracranial tumour to host metastases, the majority of which arise from breast and lung cancers.
  • We present the first report of a colonic cancer metastasis within an intracranial meningioma.A 76-year-old woman presented with a one month history of partial seizures.
  • Her medical history included resection of an adenocarcinoma of the descending colon followed by adjuvant chemotherapy 1 year before our evaluation.
  • The pathological examination demonstrated a mixture of fibrous meningioma and colloid adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Meningeal Neoplasms / secondary. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Second Primary / surgery
  • [MeSH-minor] Aged. Colectomy. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Postoperative Complications / surgery. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660939.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


59. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • INTRODUCTION: One in every thousand intracranial meningiomas metastatize extracranially.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • By the end on 2003 he developed progressively invalidating dorsolumbar pain.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Workup studies failed to reveal any primary tumor.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.
  • No postoperative complications ocurred and he is, so far, free from primary and secondary disease.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • The interval between the onset of the intracranial disease and the appearance of the metastasis varies from months to many years.
  • We believe this case represents a paradigmatic indication of this technique because it respects the concepts of radical resection and spinal stability, and offers an opportunity for the curation of the disease.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


60. Föll JL, Oettel K, Horneff G, Kunze C, Herde J: [Eyelid swelling caused by a meningioma in an 8-year-old girl. Case report and review of the diagnosis and the treatment for meningiomas in childhood and adolescence]. Klin Monbl Augenheilkd; 2006 Sep;223(9):765-70
MedlinePlus Health Information. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Eyelid swelling caused by a meningioma in an 8-year-old girl. Case report and review of the diagnosis and the treatment for meningiomas in childhood and adolescence].
  • [Transliterated title] Lidschwellung durch ein Meningeom bei einem 8-jährigen Mädchen: Fallbericht und Ubersicht über Meningeome im Kindes- und Jugendalter.
  • Orbital meningiomas are rare, particularly in childhood and adolescence.
  • CASE REPORT: We report the case of an 8-year-old girl with frontobasal meningioma, who was admitted to the hospital because of a one-sided upper eyelid swelling.
  • With the example of this case, the diagnosis, treatment and aftercare of meningiomas in childhood and adolescence will be discussed.
  • CONCLUSIONS: The treatment strategy of meningiomas in childhood requires a close interdisciplinary cooperation of ophthalmology, paediatric oncology, neurosurgery and radiotherapy.
  • Moreover, controlled investigations should yield information about the efficiency of modern irradiation techniques or adjuvant chemotherapy in the treatment of inoperable or malignant meningiomas.
  • [MeSH-major] Edema / diagnosis. Edema / etiology. Eyelid Neoplasms / complications. Eyelid Neoplasms / diagnosis. Meningioma / complications. Meningioma / diagnosis
  • [MeSH-minor] Adolescent. Child. Eyelid Diseases / complications. Eyelid Diseases / diagnosis. Female. Humans

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986088.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


61. Kutschenko A, Liebetanz D: Meningioma causing gabapentin-responsive secondary SUNCT syndrome. J Headache Pain; 2010 Aug;11(4):359-61
Hazardous Substances Data Bank. GABAPENTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma causing gabapentin-responsive secondary SUNCT syndrome.
  • Cases of symptomatic SUNCT syndromes are reported, which demonstrate that brain imaging is very important for diagnosis.
  • In this study, we describe the first case of secondary SUNCT syndrome caused by a meningioma.
  • So far, a clearly effective therapy for SUNCT syndrome has not been known.
  • This underlines that this drug is worthy of being considered as a potential therapeutic option in the treatment of SUNCT syndrome.
  • [MeSH-major] Amines / therapeutic use. Analgesics / therapeutic use. Cyclohexanecarboxylic Acids / therapeutic use. Meningeal Neoplasms / complications. Meningioma / complications. SUNCT Syndrome / etiology. gamma-Aminobutyric Acid / therapeutic use

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2006 Oct;129(Pt 10):2746-60 [16905753.001]
  • [Cites] Cephalalgia. 2007 Jul;27(7):824-32 [17598764.001]
  • [Cites] Curr Pain Headache Rep. 2008 Apr;12(2):132-7 [18474194.001]
  • [Cites] Eur J Neurol. 2006 Oct;13(10):1066-77 [16987158.001]
  • [Cites] Neurology. 2002 Jun 11;58(11):1698-9 [12058109.001]
  • [Cites] Cephalalgia. 1989 Jun;9(2):147-56 [2743414.001]
  • [Cites] Cephalalgia. 2006 May;26(5):620-2 [16674773.001]
  • [Cites] Cephalalgia. 2008 Dec;28(12):1339-42 [18727639.001]
  • (PMID = 20428918.001).
  • [ISSN] 1129-2377
  • [Journal-full-title] The journal of headache and pain
  • [ISO-abbreviation] J Headache Pain
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Amines; 0 / Analgesics; 0 / Cyclohexanecarboxylic Acids; 56-12-2 / gamma-Aminobutyric Acid; 6CW7F3G59X / gabapentin
  • [Other-IDs] NLM/ PMC2917557
  •  go-up   go-down


62. Tena-Suck M, Collado-Ortiz MA, Rembao-Bojórquez D, Gestista N, García-Marquez A: Coexistence between meningioma and tuberculosis: case report. J Neurooncol; 2010 Sep;99(2):289-94
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence between meningioma and tuberculosis: case report.
  • Intracranial tuberculoma generally presents as either solitary or multiple lesions in the brain parenchyma.
  • These are characterized by a ring-enhancing area on either computerized tomography scans or magnetic resonance images.
  • A 66 year-old female with a history of breast carcinoma at 41 years, treated with radical mastectomy and radio and chemotherapy, and rheumatoid arthritis, treated in the last 10 years, presented two months ago with occipital headache, nausea, cerebellar syndrome, alterations of speech, and memory loss.
  • Histology showed a benign meningioma with many multinuclear giant cells, granulomas, and central caseating necrosis.
  • The authors describe the unusual case of coexistence between an occipital meningioma and tuberculosis in the same area that resembled metastasis.
  • [MeSH-major] Meningeal Neoplasms / complications. Meningioma / complications. Tuberculosis, Meningeal / complications
  • [MeSH-minor] Aged. Arthritis, Rheumatoid / drug therapy. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Female. Humans. Magnetic Resonance Imaging. Mastectomy, Radical. Mycobacterium tuberculosis / pathogenicity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2008 Oct;22(5):702-4 [18661316.001]
  • [Cites] J Neuroophthalmol. 2007 Jun;27(2):91-4 [17548990.001]
  • [Cites] J Neurol. 2003 Nov;250(11):1302-6 [14648145.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1438-40 [16908553.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(2):144 [11373879.001]
  • [Cites] Neuropathology. 2008 Aug;28(4):444-7 [18282168.001]
  • [Cites] Acta Neuropathol. 1971;18(1):84-8 [5579381.001]
  • [Cites] No Shinkei Geka. 1999 Sep;27(9):837-41 [10478345.001]
  • [Cites] J Neurol Sci. 2009 Mar 15;278(1-2):123-6 [19126443.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):685-8 [8814176.001]
  • [Cites] Clin Exp Rheumatol. 2008 Jan-Feb;26(1):18-23 [18328142.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):391-406 [3383139.001]
  • [Cites] Clin Nucl Med. 2008 May;33(5):359-61 [18431158.001]
  • [Cites] Am J Clin Pathol. 1981 Jun;75(6):816-21 [6167159.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):136-9 [10632498.001]
  • [Cites] Neurol India. 2009 Mar-Apr;57(2):211-2 [19439860.001]
  • (PMID = 20195701.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Curry WT Jr, Cosgrove GR, Buchbinder BR, Ojemann RG: Resection of a dominant-hemisphere intraventricular meningioma facilitated by functional magnetic resonance imaging. Case report. Neurosurg Focus; 2001;10(6):E1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of a dominant-hemisphere intraventricular meningioma facilitated by functional magnetic resonance imaging. Case report.
  • Intraventricular meningiomas of the lateral ventricle occur relatively rarely, but they are often large at the time of detection and present more commonly on the left side.
  • Although the ability to resect these tumors safely has greatly improved over time, standard surgical approaches often traverse cortex close to areas of specific cortical function.
  • The authors used fMR imaging in planning the cortical incision for resection of a large intraventricular trigone meningioma in the dominant hemisphere of a patient who, postoperatively, suffered no aphasia or hemiparesis.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Lateral Ventricles. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neurosurgical Procedures

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724819.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Chamberlain MC, Tsao-Wei DD, Groshen S: Temozolomide for treatment-resistant recurrent meningioma. Neurology; 2004 Apr 13;62(7):1210-2
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide for treatment-resistant recurrent meningioma.
  • A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma.
  • All patients had previously been treated with surgery and involved-field radiotherapy; however, no patient had prior chemotherapy.
  • Time to tumor progression ranged from 2.5 to 5.0 months (median 5.0 months); survival ranged from 4 to 9 months (median 7.5 months).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Resistance, Neoplasm. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Neoplasm Recurrence, Local. Salvage Therapy / methods
  • [MeSH-minor] Administration, Oral. Aged. Dexamethasone / therapeutic use. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15079029.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 85622-93-1 / temozolomide
  •  go-up   go-down


65. Jouanneau E, Guzman Tovar RA, Desuzinges C, Frappaz D, Louis-Tisserand G, Sunyach MP, Jouvet A, Sindou M: Very late frontal relapse of medulloblastoma mimicking a meningioma in an adult: usefulness of 1H magnetic resonance spectroscopy and diffusion-perfusion magnetic resonance imaging for preoperative diagnosis: case report. Neurosurgery; 2006 Apr;58(4):E789; discussion E789
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late frontal relapse of medulloblastoma mimicking a meningioma in an adult: usefulness of 1H magnetic resonance spectroscopy and diffusion-perfusion magnetic resonance imaging for preoperative diagnosis: case report.
  • OBJECTIVE AND IMPORTANCE: We present a rare case of very long-term medulloblastoma relapse in an adult patient and discuss the pattern of recurrence and metabolic imaging of the tumor.
  • CLINICAL PRESENTATION: A 45-year-old man was referred for evaluation of a frontobasal midline tumor 21 years after treatment of a cerebellar medulloblastoma by surgery followed by chemotherapy and craniospinal radiotherapy.
  • Magnetic resonance images were suggestive of a meningioma.
  • Several hypotheses were discussed, such as other radio-induced tumors, sarcomas, high-grade gliomas, or lymphomas (previous chemotherapy) and even recurrence of medulloblastoma.
  • Preoperative exploration included H magnetic resonance single-voxel spectroscopy (35 and 135 ms echo time), diffusion imaging, and perfusion magnetic resonance imaging.
  • INTERVENTION: On magnetic resonance spectroscopy, N-acetyl-aspartate and an elevated choline/creatine ratio were retrieved, with a huge unidentified peak at 1.27 parts per million (ppm).
  • Myoinositol signal was present at both echo times.
  • On diffusion imaging, the tumor appeared hyperintense, with a low apparent diffusion coefficient value of 0.689.
  • Metabolic imaging favored the diagnosis of medulloblastoma over the initially suspected diagnosis of meningioma.
  • The patient underwent complete removal of the tumor that was confirmed to be a metastasis of his primary medulloblastoma.
  • The postoperative course was uneventful, and complementary courses of radiotherapy and chemotherapy were planned.
  • CONCLUSION: Late relapse should be considered, even after several decades, on occurrence of a second intracranial tumor in this context.
  • Our observation validates the clinical interest of preoperative metabolic imaging for brain tumors with distinctive pattern.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Medulloblastoma / diagnosis. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Diffusion Magnetic Resonance Imaging / methods. Humans. Magnetic Resonance Spectroscopy / methods. Male. Middle Aged. Preoperative Care / methods. Protons. Recurrence

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575298.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


66. Yang SX, Wang YR, Gan HP: [Growth-suppression effect of hydroxyurea on meningioma cells in vitro]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2004 Mar;33(2):129-32
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Growth-suppression effect of hydroxyurea on meningioma cells in vitro].
  • OBJECTIVE: To investigate the tumor-suppression effect of hydroxyurea on meningioma cells and its possible mechanism.
  • METHODS: The meningioma cells were cultured in medium containing varied doses of hydroxyurea (5x10(-3)mol/L, 5x10(-4)mol/L, 5x10(-5)mol/L), the cell growth was measured by MTT method, cell apoptosis was observed with flow cytometry (FCM).
  • CONCLUSION: Hydroxyurea can inhibit meningioma cell growth in vitro, which is most likely associated with apoptosis of the tumor cells.
  • [MeSH-major] Hydroxyurea / pharmacology. Meningioma / drug therapy
  • [MeSH-minor] Adult. Aged. Apoptosis / drug effects. Cell Division / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Female. Flow Cytometry. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15067733.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


67. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Långström B: Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res; 2001 Aug;7(8):2269-76
Hazardous Substances Data Bank. (L)-Methionine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography.
  • PURPOSE: In meningioma patients with postoperative residual masses, recurrent or primarily inoperable tumors, positron emission tomography (PET) with [(11)C]-L-methionine was used to evaluate treatment efficacy of IFN-alpha.
  • PET, computed tomography, and/or magnetic resonance imaging were performed in all patients before and, at regular intervals, during IFN-alpha treatment.
  • The ratio of tumor hot-spot uptake to cerebellar uptake or to cortex uptake was calculated.
  • This ratio estimates the relative methionine accumulation in the tumor and presumably the proliferative activity in the tumor.
  • RESULTS: During IFN-alpha treatment, PET demonstrated a mean relative percentage of reduction in the uptake ratio (MRelR) of 22.3% in the meningiomas.
  • In nine patients who were considered responders, defined as patients with a positive MRelR, the MRelR was 30.4%.
  • For the three nonresponders, defined as patients with a negative MRelR, the MRelR was -1.8%.
  • Three patients were followed for a long time: two patients for 8 years and one patient for 4 years and 6 months; the two patients followed for 8 years are still on IFN.
  • The volumes of these tumors were constant or showed a slight decrease.
  • No correlation was found between histopathological diagnosis (PAD) WHO grading I-III of meningiomas and response to IFN-alpha treatment.
  • CONCLUSIONS: PET was judged a useful method to predict which patients are suitable for long-term treatment with IFN-alpha and also for dose finding.
  • In five patients treated from 9 months to 8 years, IFN-alpha seemed to be an effective oncostatic drug.
  • [MeSH-major] Interferon-alpha / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Tomography, Emission-Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carbon Radioisotopes. Dose-Response Relationship, Drug. Female. Humans. Male. Methionine. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11489801.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Interferon-alpha; AE28F7PNPL / Methionine
  •  go-up   go-down


68. Andersen C: [Intracranial meningioma. New knowledge]. Ugeskr Laeger; 2001 May 7;163(19):2618-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial meningioma. New knowledge].
  • [Transliterated title] Meningeoma intracraniale. Ny viden.
  • Meningiomas are classified according to WHO (1993), and include eleven subtypes of benign meningiomas, two semi-malignant and one anaplastic.
  • In most cases meningiomas exhibit modifications or deletions in chromosome 22.
  • Increasing knowledge of the natural history concerning growth rate and the treatment of incidental meningiomas is accumulating.
  • Meningiomas formerly classified as surgically inaccessible are now often operable due to a continuing refinement of the surgical techniques and the study of possible new routes of intracranial tumour removal.
  • [MeSH-major] Brain Neoplasms. Meningioma
  • [MeSH-minor] Chromosome Deletion. Chromosomes, Human, Pair 22. Combined Modality Therapy. Humans. Receptors, Cell Surface / drug effects. Receptors, Cell Surface / metabolism. Risk Factors

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11360354.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, Cell Surface
  • [Number-of-references] 38
  •  go-up   go-down


69. Newton HB, Scott SR, Volpi C: Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg; 2004 Oct;18(5):495-9
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.
  • Meningiomas account for 18-20% of all intracranial tumours and often recur despite surgical resection.
  • Hydroxyurea is under evaluation as adjuvant therapy of meningiomas.
  • In the authors' initial report of 17 patients with meningioma, hydroxyurea demonstrated modest efficacy, with a median time to progression (TTP) of 80 weeks.
  • In the current study, 21 patients with meningioma have been placed on hydroxyurea (20 mg/kg/day orally), with extended follow-up of the original cohort.
  • Eighteen of 20 evaluable patients (90%) responded with stable disease ranging from 20 to 328 + weeks (median TTP 176 weeks; 11 patients censored).
  • Two patients had progressive disease after 10 weeks.
  • Hydroxyurea has modest activity against meningiomas and should be considered for patients who are poor surgical candidates, have unresectable or large residual meningiomas, or have progressed after surgical resection or irradiation, or both.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Evaluation. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15799152.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


70. Hasan R, Marshall MC Jr, Medhi M, Arshad A, Braun A, Panageas E: Meningioma metastatic to thyroid gland. Endocr Pract; 2001 Sep-Oct;7(5):370-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma metastatic to thyroid gland.
  • OBJECTIVE: To describe the first reported case of meningioma metastasizing to and completely infiltrating the thyroid gland.
  • METHODS: We present a detailed case report, including radiographic, histologic, and immunostaining findings, in a patient with an atypical meningioma who had a progressively enlarging thyroid mass that proved to be a metastatic meningioma.
  • RESULTS: A 49-year-old man had a meningioma in the parieto-occipital region that had spread locally to the scalp and bone by the time of surgical resection.
  • Local recurrence during the following year prompted repeated surgical resection, tumor embolization, radiotherapy, and chemotherapy.
  • Despite aggressive therapy, the tumor progressed.
  • A thyroid mass was first noted 2 years after the meningioma was diagnosed.
  • Histologic examination of the thyroidectomy specimen showed that the thyroid gland had been extensively replaced by metastatic meningioma.
  • CONCLUSION: To our knowledge, this is the first reported case of metastatic meningioma extensively infiltrating the thyroid gland.
  • This case report expands the spectrum of tumors that metastasize to the thyroid gland.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / secondary. Thyroid Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Embolization, Therapeutic. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy. Reoperation. Thyroidectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11585373.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


71. Gupta R, Suri V, Jain A, Sharma MC, Sarkar C, Singh MM, Joshi NP, Puri T, Julka PK: Anaplastic meningioma in an adolescent: a report of a rare case and brief review of literature. Childs Nerv Syst; 2009 Feb;25(2):241-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma in an adolescent: a report of a rare case and brief review of literature.
  • OBJECTIVE: Anaplastic meningioma is an uncommon neoplasm in childhood and adolescence.
  • Due to the rarity, treatment options for anaplastic meningioma in this age group are not clearly outlined.
  • CASE: A 15-year-old boy presented with a left forehead swelling with a history of a left frontal tumor.
  • Radiological investigations revealed a dura-based tumor with a large extracranial and a smaller intracranial component.
  • Craniotomy with near-total excision of the tumor was performed.
  • Histopathological examination of the tumor showed features of an anaplastic meningioma.
  • The patient is currently receiving radiotherapy and chemotherapy.
  • However, he has developed scalp swellings while on radiotherapy.
  • CONCLUSION: Anaplastic meningioma is extremely rare in children.
  • Extensive sampling is required to recognize the meningothelial nature of the tumor and immunohistochemistry helps in making an accurate diagnosis in such cases.
  • Therapeutic interventions in such cases need to be closely monitored due to the aggressive behavior of this tumor.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Mucin-1 / analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Child Neurol. 2006 Jan;21(1):31-6 [16551450.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):1-7 [15886506.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):179-82 [14758946.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Expert Rev Neurother. 2006 Oct;6(10):1447-64 [17078786.001]
  • [Cites] Childs Brain. 1980;7(1):43-56 [7428495.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] Childs Nerv Syst. 1986;2(3):160-1 [3779674.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Neurol Med Chir (Tokyo). 1978;18(1 Pt 1):119-27 [77488.001]
  • (PMID = 18769931.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mucin-1; 0 / Vimentin
  • [Number-of-references] 11
  •  go-up   go-down


72. Park YS, Lee JH, Bondar J, Harwalkar JA, Safayhi H, Golubic M: Cytotoxic action of acetyl-11-keto-beta-boswellic acid (AKBA) on meningioma cells. Planta Med; 2002 May;68(5):397-401
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic action of acetyl-11-keto-beta-boswellic acid (AKBA) on meningioma cells.
  • Because pentacyclic triterpenes have antiproliferative and cytotoxic effects against different tumor types, we investigated whether AKBA would act in a similar fashion on primary human meningioma cell cultures.
  • Primary cell cultures were established from surgically removed meningioma specimens.
  • Treatment of meningioma cells by AKBA revealed a potent cytotoxic activity with half-maximal inhibitory concentrations in the range of 2 - 8 microM.
  • At low micromolar concentrations, AKBA rapidly and potently inhibited the phosphorylation of Erk-1/2 and impaired the motility of meningioma cells stimulated with platelet-derived growth factor BB.
  • The cytotoxic action of AKBA on meningioma cells may be mediated, at least in part, by the inhibition of the Erk signal transduction pathway.
  • [MeSH-minor] Cell Movement / drug effects. Humans. Immunoblotting. Inhibitory Concentration 50. Meningioma / drug therapy. Meningioma / pathology. Mitogen-Activated Protein Kinase 1 / drug effects. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3. Mitogen-Activated Protein Kinases / drug effects. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation / drug effects. Plant Extracts / pharmacology. Signal Transduction. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12058313.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Lipoxygenase Inhibitors; 0 / Plant Extracts; 0 / Triterpenes; 0 / acetyl-11-ketoboswellic acid; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


73. Miyazawa T, Uozumi Y, Toyooka T, Shima K: Hemorrhage from a falx meningioma after internal use of low-dose aspirin. J Stroke Cerebrovasc Dis; 2008 Sep;17(5):325-7
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemorrhage from a falx meningioma after internal use of low-dose aspirin.
  • We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.
  • Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.
  • On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.
  • Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.
  • [MeSH-major] Aspirin / adverse effects. Fibrinolytic Agents / adverse effects. Intracranial Hemorrhages / chemically induced. Meningeal Neoplasms / complications. Meningioma / complications
  • [MeSH-minor] Aged. Cerebral Infarction / drug therapy. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755414.001).
  • [ISSN] 1532-8511
  • [Journal-full-title] Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  • [ISO-abbreviation] J Stroke Cerebrovasc Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; R16CO5Y76E / Aspirin
  •  go-up   go-down


74. Fan YP, Hu YM, Li Y: [Antifebrile effect of naoreqing oral liquid on post-operational fever of glioma or meningioma patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2001 Jun;21(6):406-8
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antifebrile effect of naoreqing oral liquid on post-operational fever of glioma or meningioma patients].
  • OBJECTIVE: To observe the antifebrile effect of Naoreqing (NRQ) oral liquid on fever in patients after glioma or meningioma operation.
  • The treatment was applied for 7 successive days.
  • The mean time of fever and fever subsidence, body temperature before and after treatment were recorded and compared.
  • CONCLUSION: NRQ can evidently reduce the body temperature of patients after brain tumor operation, its antifebrile effect is irrelevant to the kind of tumor being glioma or meningioma.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12577430.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


75. Lee KL, Terris MK: Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology; 2003 Aug;62(2):351
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma.
  • The relative contraindication of hormonal therapy for patients with prostate cancer and a history of meningioma has not been widely emphasized.
  • Using immunohistochemistry to determine the presence of hormone receptors in meningioma specimens proved potentially valuable in 2 patients with biochemical recurrence after prostatectomy who were being considered for androgen deprivation therapy.
  • These cases also highlight the need for caution against assuming that skull-based intracranial growths in patients receiving hormonal therapy for prostate cancer are metastatic lesions rather than hormonally induced primary tumors.
  • [MeSH-major] Gonadotropin-Releasing Hormone / adverse effects. Gonadotropin-Releasing Hormone / agonists. Meningeal Neoplasms / chemically induced. Meningioma / chemically induced
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / chemically induced. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / chemically induced. Prostatectomy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12893358.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


76. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol; 2006 Jul;29(1):25-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
  • Tissue factor pathway inhibitor 2 (TFPI-2) is a 32-kDa extracellular matrix-associated kunitz-type serine proteinase inhibitor.
  • It is secreted by all vascular cells and plays a role in tumor invasion and metastasis, presumably by plasmin-mediated matrix remodeling.
  • Previous studies have shown high expression of TFPI-2 by benign tumors and low or absent expression in highly malignant tumors.
  • Malignant meningiomas constitute 10-15% of all meningiomas and our previous studies revealed loss of expression of TFPI-2 in malignant gliomas.
  • To investigate the role of TFPI-2 in the invasiveness of malignant meningiomas, we stably transfected the human meningioma cell line, IOMM-Lee, with a vector capable of expressing a transcript complementary to the full length of TFPI-2 mRNA in a sense orientation.
  • Finally, TFPI-2 overexpression inhibited intracranial tumor formation in nude mice.
  • Our data substantiate our previous observation that TFPI-2 plays an important role in tumor progression and has potential in anti-cancer therapy.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Feb 20;317(1):311-4 [7872799.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] J Biochem. 1994 Nov;116(5):939-42 [7896752.001]
  • [Cites] Arch Biochem Biophys. 1995 May 10;319(1):55-62 [7539605.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):310-6 [8631347.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):267-8 [8661135.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):40-6 [9445254.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2698-703 [9531578.001]
  • [Cites] Placenta. 1998 Mar-Apr;19(2-3):217-23 [9548189.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):749-56 [9610735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] Semin Thromb Hemost. 1998;24(3):207-10 [9701449.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cell Death Differ. 1999 Jul;6(7):673-82 [10453078.001]
  • [Cites] Arch Biochem Biophys. 1999 Oct 1;370(1):112-8 [10496984.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):379-83 [7861006.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):127-31 [11115549.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12241-8 [11278667.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):239-44 [11315097.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):591-7 [11494041.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):325-33 [11606093.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6938-45 [11687973.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7758-64 [2253219.001]
  • [Cites] J Biochem. 1990 Oct;108(4):537-43 [1963430.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5046-53 [1387587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • (PMID = 16773181.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Lipoproteins; 0 / Proteoglycans; 0 / bcl-2-Associated X Protein; 0 / lipoprotein-associated coagulation inhibitor; 0 / tissue-factor-pathway inhibitor 2; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS9141; NLM/ PMC1479607
  •  go-up   go-down


77. Fukushima Y, Oka H, Utsuki S, Iwamoto K, Fujii K: Nevoid Basal cell carcinoma syndrome with medulloblastoma and meningioma--case report. Neurol Med Chir (Tokyo); 2004 Dec;44(12):665-8
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid Basal cell carcinoma syndrome with medulloblastoma and meningioma--case report.
  • A 35-year-old man presented with a rare case of nevoid basal cell carcinoma syndrome, or Gorlin's syndrome, associated with both medulloblastoma and meningioma, manifesting as visual field constriction due to multiple parasellar tumors.
  • He had undergone resection of a medulloblastoma at the age of 1 year 9 months, followed by adjunctive irradiation with a total dose of 40 Gy.
  • Histological examination of biopsy specimens established the diagnosis of nevoid basal cell carcinoma syndrome.
  • Tuberculum sellae meningioma was removed through a craniotomy, and his symptoms improved.
  • Meningioma is known to occur in the field of therapeutic irradiation, so chemotherapy may be a better option for medulloblastoma associated with nevoid basal cell carcinoma syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome. Cerebellar Neoplasms. Medulloblastoma. Meningeal Neoplasms. Meningioma. Neoplasms, Second Primary

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15684600.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


78. Lubnin AIu, Konovalov AN, Markina MS, Goriachev AS: [Massive pulmonary artery thromboembolism after removal of sphenoid wing meningioma (clinical case with good outcome)]. Zh Vopr Neirokhir Im N N Burdenko; 2004 Jan-Mar;(1):32-6
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Massive pulmonary artery thromboembolism after removal of sphenoid wing meningioma (clinical case with good outcome)].
  • [Transliterated title] Massivnaia tromboémboliia legochnoĭ arterii posle udaleniia meningiomy kryl'ev osnovnoĭ kosti (klinicheskoe nabliudenie s blagopriiatnym iskhodom).
  • The paper describes a clinical case of the severe potentially fatal postoperative complication--massive pulmonary thromboembolism--in a patient after uncomplicated removal of meningioma of the wing of os basilare.
  • It also describes the problems in the diagnosis, treatment, prevention of perioperative deep venous thrombosis of the shin and subsequent pulmonary thromboembolism in neurosurgery patients.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Postoperative Complications / drug therapy. Pulmonary Embolism / drug therapy. Sphenoid Bone / surgery
  • [MeSH-minor] Adult. Anticoagulants / therapeutic use. Female. Humans. Neurosurgical Procedures. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15055010.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


79. Stienen MN, Lücke S, Fournier JY, Hildebrandt G, Gautschi OP: [The intracranial meningioma - therapeutic possibilities and limitations]. Praxis (Bern 1994); 2010 Dec 1;99(24):1479-94
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The intracranial meningioma - therapeutic possibilities and limitations].
  • [Transliterated title] Das intrakranielle Meningeom - Therapeutische Möglichkeiten und Grenzen.
  • Meningiomas are common intracranial tumours that arise from arachnoidal cells.
  • Clinically they often manifest by headache, focal or generalized seizures, or neurologic deficits as a result of brain compression.
  • More than 90 percent of these mostly slow growing meningiomas are benign.
  • Stereotactic radiotherapy as initial treatment is an effective alternative for meningiomas, especially in patients not suitable for surgery due to various reasons.
  • In patients that are refractory to treatment or with unresectable disease a hormonal- or chemotherapy can be considered.
  • [MeSH-major] Meningeal Neoplasms / therapy
  • [MeSH-minor] Algorithms. Brain / pathology. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Cross-Sectional Studies. Humans. Magnetic Resonance Imaging. Prognosis. Radiosurgery. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21125533.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


80. Chen YY, Tiang XY, Li Z, Luo BN, Huang Q: Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature. Diagn Pathol; 2010;5:39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature.
  • Meningioangiomatosis is a rare hamartomatous lesion or meningiovascular malformation in brain.
  • In extremely rare condition, meningioma may occur together with meningioangiomatosis, and only 19 cases have been described in English literature until now.
  • We now report a case of meningioangiomatosis-associated meningioma with atypical and clear cell variant.
  • He had no stigmata of neurofibromatosis type 2.
  • Microscopically, parts of lesions were atypical and clear cell meningioma corresponding to WHO grade II.
  • The adjacent brain parenchyma showed the histological features of meningioangiomatosis.
  • Neoplastic cells in atypical meningioma area were immunoreactive to epithelial membrane antigen (EMA) with high MIB-1 index of up to 20%.
  • The diagnosis of atypical meningioma associated with sporadic meningioangiomatosis was made.
  • To our knowledge, this is the first case of a meningioangiomatosis-associated meningioma with atypical and clear cell variant component to be described.
  • The patient had been followed-up for 11 months without adjuvant radiotherapy or chemotherapy.
  • No tumor recurrence was found during this period.
  • Meningioangiomatosis-associated meningioma is more likely to occur in younger patients and histologically to mimic parenchymal invasion of brain.
  • We suggest that postoperative radiotherapy or chemotherapy should be given careful consideration to avoid over-treatment due to erroneously interpret as malignant meningioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Vascular Malformations / diagnosis. Cerebral Cortex / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Apr;92(4):706-10 [10761664.001]
  • [Cites] Acta Cytol. 2009 Jan-Feb;53(1):93-7 [19248561.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):568-72 [11826364.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):48-56 [11849563.001]
  • [Cites] Nervenarzt. 2002 Oct;73(10):990-4 [12376888.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Apr;29(2):170-4 [12662324.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):643-5 [14655769.001]
  • [Cites] Am J Clin Pathol. 1974 Oct;62(4):481-7 [4212953.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Acta Neuropathol. 1987;73(4):361-4 [3618128.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):715-9 [2213161.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):145-7 [1594484.001]
  • [Cites] J Neurosurg. 1993 Feb;78(2):287-9 [8421212.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):485-9 [9143261.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):872-5 [10435554.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):78-83 [16389566.001]
  • [Cites] Surg Neurol. 2006 Jun;65(6):595-603 [16720184.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):125-9 [11756780.001]
  • (PMID = 20565869.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904739
  •  go-up   go-down


81. Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, Masuo O, Naito Y: Regression of a presumed meningioma with the antiestrogen agent mepitiostane. Case report. J Neurosurg; 2000 Jul;93(1):132-5
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of a presumed meningioma with the antiestrogen agent mepitiostane. Case report.
  • This 68-year-old woman underwent a distal gastrectomy for gastric cancer in August 1994.
  • A presumed meningioma of the falx was found incidentally on a staging examination of the gastric cancer, but the meningioma was not treated with surgery.
  • Instead, after gastrectomy the patient received tegafur as adjuvant chemotherapy until February 1996, when she was readmitted to the hospital because of loss of appetite and emaciation but with no recurrence of the gastric cancer.
  • A computerized tomography scan obtained during this second admission showed no change in the meningioma.
  • Administration of mepitiostane for approximately 2 years resulted in a marked regression (73%) of the meningioma.
  • This is the first reported case of a presumed meningioma that regressed as a result of use of the antiestrogen agent mepitiostane.
  • [MeSH-major] Androstanols / therapeutic use. Antineoplastic Agents / therapeutic use. Estrogen Antagonists / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy
  • [MeSH-minor] Adenocarcinoma, Papillary / surgery. Aged. Female. Gastrectomy. Humans. Postoperative Complications / drug therapy. Postoperative Complications / radiography. Stomach Neoplasms / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10883917.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Androstanols; 0 / Antineoplastic Agents; 0 / Estrogen Antagonists; O00404969K / mepitiostane
  •  go-up   go-down


82. Drevelegas A, Xinou E, Karacostas D, Parissis D, Karkavelas G, Milonas I: Meningioma growth and interferon beta-1b treated multiple sclerosis: coincidence or relationship? Neuroradiology; 2005 Jul;47(7):516-9
Hazardous Substances Data Bank. Interferon Beta-1b .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma growth and interferon beta-1b treated multiple sclerosis: coincidence or relationship?
  • Although the coincidence of multiple sclerosis (MS) and central nervous system (CNS) tumors has been reported in over 30 cases in English literature, meningioma growth was associated with interferon-beta (INF-b) treated MS only in two of them.
  • We report the case of a 19-year-old woman with clinically possible, laboratory supported MS, and a concomitant right intraventricular tumor with magnetic resonance imaging (MRI) characteristics consistent with meningioma (similar signal with grey matter on T1 and T2-weighted images and homogenous, intense enhancement).
  • Two years after initiation of INF-b treatment, follow-up brain MRI revealed enlargement of the intraventricular mass and relative increase in the number of white matter lesions without significant clinical deterioration.
  • She underwent almost total resection of the mass and histology confirmed the diagnosis of papillary meningioma.
  • Based on the immunohistochemistry results, we speculate that INF-b resulted in meningioma growth by enhancing platelet derived growth factor (PDGF) receptors or/and down-regulating transforming growth factor receptors on the tumor itself.
  • [MeSH-major] Adjuvants, Immunologic / adverse effects. Cerebral Ventricle Neoplasms / diagnosis. Interferon-beta / adverse effects. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Multiple Sclerosis / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):717-23 [8687119.001]
  • [Cites] N Engl J Med. 1997 Apr 17;336(16):1163-71 [9099662.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] Neurology. 2002 Sep 24;59(6):802-8 [12349849.001]
  • [Cites] Acta Neurol Scand. 1991 Sep;84(3):214-20 [1950464.001]
  • [Cites] Arq Neuropsiquiatr. 2000 Dec;58(4):1133-7 [11105086.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1961-6 [7525845.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):216-8 [1564485.001]
  • [Cites] Surg Neurol. 1986 Jul;26(1):45-51 [3715699.001]
  • [Cites] Ann Neurol. 2001 Jun;49(6):776-85 [11409430.001]
  • [Cites] Eur Neurol. 1980;19(3):192-7 [7389764.001]
  • [Cites] Semin Cancer Biol. 1992 Apr;3(2):89-96 [1378314.001]
  • [Cites] J Neurol. 1978 Apr 14;218(1):23-33 [77315.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] Neurology. 1997 May;48(5):1330-3 [9153467.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):440-6 [10470819.001]
  • [Cites] Acta Neurochir (Wien). 2002 Apr;144(4):365-8 [12021883.001]
  • (PMID = 15981002.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 145155-23-3 / Interferon beta-1b; 77238-31-4 / Interferon-beta; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


83. Bodner-Adler B, Lozano P, Bodner K, Zeisler H: Primary uterine leiomyosarcoma and primary atypical meningioma diagnosed during pregnancy. Anticancer Res; 2008 Sep-Oct;28(5B):3083-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary uterine leiomyosarcoma and primary atypical meningioma diagnosed during pregnancy.
  • The incidence of meningioma during pregnancy is comparable with that in nonpregnant women of the same age group.
  • We report a case of both--a primary uterine leiomyosarcoma and additionally an atypical meningioma of the brain both diagnosed during pregnancy.
  • A tumoural mass was detected and initial conservative treatment was started.
  • During caesarean section a pedunculated uterine fibroid was removed and total gross resection due to the brain tumour was also performed.
  • Histopathological diagnosis of both tumours revealed an atypical meningioma of the brain and a uterine leiomyosarcoma.
  • The patient underwent laparatomy and received six cycles of adjuvant chemotherapy.
  • Treatment options seem to be reduced in pregnant women and mainly depend on the patient's condition as well as the gestational age at presentation.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leiomyosarcoma / diagnosis. Meningioma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Uterine Neoplasms / diagnosis


84. Ammerlaan AC, Houben MP, Tijssen CC, Wesseling P, Hulsebos TJ: Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation. Childs Nerv Syst; 2008 Jul;24(7):855-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation.
  • OBJECTIVE: We report on a patient who developed a meningioma more than two decades after removal at a young age of an atypical teratoid/rhabdoid tumour (AT/RT), which was due to a germline INI1 mutation, and radio- and chemotherapy.
  • MATERIALS AND METHODS: We present genetic evidence that the meningioma is not a recurrence or metastasis of the AT/RT and not due to the INI1 mutation, but is a radiation-induced tumour.
  • CONCLUSION: This is the first case illustrating that improved survival of young patients with an AT/RT after aggressive treatment may be gained at the cost of an increased risk for the development of radiation-induced, non-INI1-related tumours.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. DNA-Binding Proteins / genetics. Meningioma / secondary. Mutation / genetics. Rhabdoid Tumor / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adult. Genetic Predisposition to Disease. Humans. Loss of Heterozygosity. Male. Polymorphism, Single Nucleotide. Radiotherapy / adverse effects. Radiotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Apr;66(4):1403-6 [10739763.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):614-20 [10901233.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1002-13 [15200115.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):474-9 [18087273.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E9 [16398473.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):279-84 [16261613.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):97-111 [16855864.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Aug;13(4):272-7 [7547635.001]
  • (PMID = 18236049.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2413122
  •  go-up   go-down


85. Giordano F, Savarino A, Pagni CA: Spinal meningioma during hydroxyurea therapy. A paradoxycal case report. Neurol Sci; 2002 Sep;23(3):127-9
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal meningioma during hydroxyurea therapy. A paradoxycal case report.
  • We report the case of a 65-year-old woman who developed symptoms of spinal cord compression due to a spinal meningioma after 10 years of treatment with hydroxyurea (1000 mg/day) for essential thrombocytemia.
  • This case provides a paradigm for the occurrence of symptomatic meningioma in course of HU therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Spinal Cord / drug effects. Thrombocythemia, Essential / complications. Thrombocythemia, Essential / drug therapy
  • [MeSH-minor] Aged. Cervical Vertebrae. Female. Humans. Laminectomy. Magnetic Resonance Imaging. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12391498.001).
  • [ISSN] 1590-1874
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


86. Mori Y, Kondo T, Iwakoshi T, Kida Y, Kobayashi T, Yoshimoto M, Hasegawa T: Malignant lymphoma arising in the cerebral parenchyma adjacent to a parasagittal meningioma. Neurol Med Chir (Tokyo); 2006 Aug;46(8):398-400
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma arising in the cerebral parenchyma adjacent to a parasagittal meningioma.
  • A 70-year-old woman with an asymptomatic parasagittal meningioma had been under observation with follow-up imaging for 2 years.
  • She gradually developed motor weakness in the left hand.
  • Magnetic resonance (MR) imaging disclosed a newly developed well-enhanced area in the cerebral parenchyma adjacent to the stable original meningioma.
  • We suspected that the meningioma had enlarged into the brain parenchyma, although MR imaging suggested a border between the extra-axial and intra-axial portions.
  • Two separate tumors were identified with quite different histological features.
  • The extra-axial tumor was identified as benign transitional meningioma and the intra-axial tumor as diffuse large cell type malignant lymphoma.
  • The original site of the lymphoma remained free from relapse, but another lesion developed in the right frontal lobe 3 months later and chemotherapy was performed.
  • The main concern for follow-up imaging of asymptomatic meningioma without surgical resection is growth of the meningioma.
  • However, development of new different tumors is possible, although thought to be rare.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / pathology. Lymphoma / complications. Lymphoma / pathology. Meningeal Neoplasms / complications. Meningeal Neoplasms / pathology. Meningioma / complications. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936461.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Travitzky M, Libson E, Nemirovsky I, Hadas I, Gabizon A: Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma. Anticancer Drugs; 2003 Mar;14(3):247-50
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma.
  • Metastatic meningioma is a rare disease, which has no effective chemotherapy.
  • We report on a treatment of this condition with Doxil, a liposomal doxorubicin formulation.
  • A 60-year-old woman with massive pleuro-pulmonary metastases from recurrent cranial meningioma was treated with Doxil (50-37.5 mg/m2) for 18 months with near-complete resolution of metastases and disappearance of pleural fluid.
  • Doxil was cleared very slowly in this patient with a monoexponential half-life of 108 h.
  • The patient remains in near-complete response for 6 months after treatment discontinuation.
  • This is the first report on an effective chemotherapy in a patient with typical metastatic meningioma.
  • The exact mechanism accounting for such an effective drug action is not clear, but may be related to a particularly high microvascular permeability to the liposome carriers in these metastatic lesions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Lung Neoplasms / drug therapy. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Lippincott Williams & Wilkins
  • (PMID = 12634620.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  •  go-up   go-down


88. Kawahara I, Masui K, Horie N, Matsuo T, Kitagawa N, Tsutsumi K, Nagata I, Morikawa M, Hayashi T: Radiation-induced meningioma following prophylactic radiotherapy for acute lymphoblastic leukemia in childhood. Pediatr Neurosurg; 2007;43(1):36-41
Genetic Alliance. consumer health - Radiation induced meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced meningioma following prophylactic radiotherapy for acute lymphoblastic leukemia in childhood.
  • Although it was considered to be a poor prognostic disease, modern treatment protocols (aggressive chemotherapy and prophylactic cranial irradiation) have resulted in dramatically improved survival rates.
  • However, ALL patients who undergo this treatment are at risk of developing secondary neoplasms related to treatment, which has become an increasingly recognized problem.
  • CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).
  • Computed tomography and magnetic resonance imaging revealed a parasagittal tumor of the left frontoparietal lobe with perifocal edema.
  • The tumor was completely removed surgically and pathohistologically diagnosed as atypical meningioma.
  • CONCLUSION: Long-term survivors who received radiotherapy for ALL in childhood are at risk for late complications, including radiation-induced meningioma.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / etiology. Meningioma / diagnosis. Meningioma / etiology. Neoplasms, Radiation-Induced / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Child, Preschool. Humans. Male. Radiotherapy / adverse effects. Time Factors


89. Menon R, Muzumdar D, Shah A, Goel A: Glioblastoma multiforme following cranial irradiation and chemotherapy for acute lymphocytic leukaemia. Report of 3 cases. Pediatr Neurosurg; 2007;43(5):369-74
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme following cranial irradiation and chemotherapy for acute lymphocytic leukaemia. Report of 3 cases.
  • The most common secondary neoplasms which occur following cranial radiation therapy are sarcoma and meningioma.
  • The occurrence of glioblastoma multiforme following radiation and chemotherapy in acute lymphocytic leukaemia (ALL) is rare.
  • We report 3 cases of glioblastoma multiforme in children developing 11-72 months following completion of chemotherapy/radiotherapy for ALL.
  • The exact cause for the development of glioblastoma multiforme following therapy for ALL is not clear.
  • A genetic predisposition may be essential for the occurrence of such a highly malignant primary brain tumour in leukaemia patients, irrespective of radiation and/or chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17786001.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic
  •  go-up   go-down


90. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R: Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest; 2006 Dec;24(8):727-33
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
  • BACKGROUND: Mifepristone (RU486) is an oral antiprogestational and, to a lesser extent, antiglucocorticoid agent commonly used for short-term (single-day) therapy.
  • However, treatment of neoplasms or chronic conditions will require long-term administration.
  • Meningioma is a benign central nervous system tumor that is often progesterone-but not estrogen-receptor positive, making long-term antiprogestational therapy a logical treatment strategy.
  • METHODS: Patients with unresectable meningioma were treated with oral mifepristone 200 mg/day.
  • Serial follow-up allowed evaluation for tolerability and side effects of long-term therapy as well as observation for efficacy (tumor shrinkage or improvement in visual fields).
  • RESULTS: Twenty-eight patients received daily oral mifepristone for a total of 1,626 patient-months of treatment.
  • The median duration of therapy was 35 months (range 2-157 months).
  • However, endometrial hyperplasia or polyps were documented in 3 patients and one patient developed peritoneal adenocarcinoma after 9 years of therapy.
  • In view of the association between long-term treatment with tamoxifen (another agent that can induce an unopposed estrogen effect) and endometrial cancer, this observation will require further investigation and screening.
  • Minor regression of meningioma that can result in significant clinical benefit is suggested in the male and premenopausal female subgroups of patients.
  • [MeSH-major] Contraceptives, Oral, Synthetic / administration & dosage. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Mifepristone / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162554.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2P30 CA14089
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Synthetic; 320T6RNW1F / Mifepristone
  •  go-up   go-down


91. Ahn JY, Choi EW, Kang SH, Kim YR: Isolated meningeal chloroma (granulocytic sarcoma) in a child with acute lymphoblastic leukemia mimicking a falx meningioma. Childs Nerv Syst; 2002 Apr;18(3-4):153-6
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated meningeal chloroma (granulocytic sarcoma) in a child with acute lymphoblastic leukemia mimicking a falx meningioma.
  • BACKGROUND: Isolated chloromas (granulocytic sarcomas) are rare tumors.
  • When dural-based, granulocytic sarcoma may be indistinguishable from meningioma radiologically.
  • CASE HISTORY: We now describe one patient affected by ALL with isolated granulocytic sarcoma mimicking meningioma as initial CNS relapses.
  • A 12-year-old girl who had been diagnosed with ALL and undergone chemotherapy presented with generalized tonic-clonic seizure while in complete remission.
  • Computed tomographic scan and magnetic resonance imaging showed a small mass mimicking a meningioma at the anterior falx.
  • The patient was developed speech disturbance 6 days later.
  • The pathological diagnosis was acute lymphoblastic leukemia.
  • Early detection and antileukemic treatment of granulocytic sarcoma are necessary and important for a favorable prognosis.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981624.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Hensiek AE, Kellerman AJ, Hill JT: Spontaneous regression of a solitary cerebral metastases in renal carcinoma followed by meningioma development under medroxyprogesterone acetate therapy. Br J Neurosurg; 2000 Aug;14(4):354-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of a solitary cerebral metastases in renal carcinoma followed by meningioma development under medroxyprogesterone acetate therapy.
  • A case of regression of a probable cerebral metastasis of a hypernephroma after nephrectomy and hormone therapy is presented.
  • The patient subsequently developed a meningioma after therapy with medroxyprogesterone acetate.
  • A relationship between meningioma growth and sex hormones has been documented, but little is known about the effect of hormone therapies on tumour growth.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / drug therapy. Meningioma / chemically induced. Neoplasm Regression, Spontaneous. Neoplasms, Second Primary / chemically induced

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11045205.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


93. Jung DI, Park C, Kang BT, Kim JW, Kim HJ, Lim CY, Jeong SW, Park HM: Acquired cervical syringomyelia secondary to a brainstem meningioma in a maltese dog. J Vet Med Sci; 2006 Nov;68(11):1235-8
SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired cervical syringomyelia secondary to a brainstem meningioma in a maltese dog.
  • A mass was noted in the brainstem on brain magnetic resonance images.
  • Based on diagnostic imaging findings, cervical syringomyelia secondary to a brainstem tumor was suspected.
  • The clinical signs were controlled well by lomustine and the dog survived for 8 months after the initial diagnosis.
  • The mass was diagnosed as a meningioma based on histopathological findings.
  • This report describes the clinical findings and imaging characteristics of an acquired syringomyelia resulting from a brainstem meningioma.

  • MedlinePlus Health Information. consumer health - Syringomyelia.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146188.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7BRF0Z81KG / Lomustine
  •  go-up   go-down


94. Pavlou G, Pal D, Bucur S, Chakrabarty A, van Hille PT: Intracranial non-Hodgkin's MALT lymphoma mimicking a large convexity meningioma. Acta Neurochir (Wien); 2006 Jul;148(7):791-3; discussion 793
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial non-Hodgkin's MALT lymphoma mimicking a large convexity meningioma.
  • Recently these B cell lymphomas of mucosa associated lymphoid tissue (MALT) have gained acceptance as an important pathological subtype and are distinguishable from other primary CNS lymphomas that exhibit aggressive behaviour.
  • Over the past decade a number of these lesions have been reported to resemble a meningioma both intra-operatively and radiologically.
  • The authors outline such a case of marginal zone B cell lymphoma that clinically and radiologically resembled a meningioma.
  • This case illustrates the rare occurrence of low grade dural B cell lymphoma and the need to consider this entity in the differential diagnosis of CNS lesions, if appropriate targeted therapy is to be administered.
  • [MeSH-major] Dura Mater / pathology. Lymphoma, B-Cell, Marginal Zone / radiography. Meningeal Neoplasms / radiography
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Meningioma / diagnosis. Neurosurgical Procedures. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / physiopathology. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / physiopathology. Postoperative Hemorrhage / therapy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570114.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


95. Kunikata H, Tamai M: Cilioretinal artery occlusions following embolization of an artery to an intracranial meningioma. Graefes Arch Clin Exp Ophthalmol; 2006 Mar;244(3):401-3
Hazardous Substances Data Bank. POLYVINYL ALCOHOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cilioretinal artery occlusions following embolization of an artery to an intracranial meningioma.
  • PURPOSE: To report a case in which a prophylactic embolization of a feeder artery to an intarcranial meningioma led to an occlusion of a cilioretinal artery.
  • METHODS: A 48-year-old man with an intracranial meningioma presented with ocular pain and visual loss in his right eye following embolization of a feeder artery to the meningioma with polyvinyl alcohol.
  • CONCLUSIONS: Our case demonstrated that an occlusion of a retinal artery can be a complication of preoperative embolization of an artery to an intracranial tumor and can lead to severe visual loss.
  • [MeSH-major] Chemoembolization, Therapeutic / adverse effects. Ciliary Arteries / pathology. Meningeal Arteries / drug effects. Meningeal Neoplasms / therapy. Meningioma / therapy. Retinal Artery Occlusion / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 1991 Apr;98 (4):527-31 [2052308.001]
  • [Cites] Am J Ophthalmol. 2004 Sep;138(3):496-8 [15364244.001]
  • [Cites] Am J Ophthalmol. 2000 May;129(5):690-1 [10844076.001]
  • [Cites] Am J Ophthalmol. 1985 May 15;99(5):586-9 [4003497.001]
  • [Cites] Arch Ophthalmol. 2002 Jun;120(6):857-60 [12049601.001]
  • [Cites] Acta Ophthalmol Scand. 1999 Dec;77(6):717-8 [10634572.001]
  • [Cites] J Neurosurg. 1974 Sep;41(3):396-8 [4415192.001]
  • (PMID = 16059705.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-89-5 / Polyvinyl Alcohol
  •  go-up   go-down


96. Tu PH, Giannini C, Judkins AR, Schwalb JM, Burack R, O'Neill BP, Yachnis AT, Burger PC, Scheithauer BW, Perry A: Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol; 2005 Aug 20;23(24):5718-27
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.
  • The aim of this study is to elucidate the biology and genetic features of this unusual tumor.
  • RESULTS: CNS MZBCLs preferentially affect middle-aged women (female-to-male ratio, 4:1), with 93% presenting as dural-based masses mimicking meningioma.
  • Ten patients with 1 to 7.6 years of follow-up after diagnosis showed no evidence of disease after radiation and/or chemotherapy.
  • CONCLUSION: Our data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass.
  • Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality that may contribute to the pathogenesis of this CNS lymphoma.
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 3. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Meningioma / pathology. Middle Aged. Translocation, Genetic. Trisomy

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009945.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Tamura S, Tamura Y, Ohoka A, Hasegawa T, Uchida K: A canine case of skull base meningioma treated with hydroxyurea. J Vet Med Sci; 2007 Dec;69(12):1313-5
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A canine case of skull base meningioma treated with hydroxyurea.
  • An 11-year-old female miniature schnauzer was tentatively diagnosed with the skull base meningioma, based on several examinations.
  • Because surgical treatment was difficult, and outpatient radiation therapy was not available in the local area, chemotherapy with hydroxyurea combined with dexamethasone was selected.
  • The patient's clinical symptoms improved after one week of treatment, and the tumor size was obviously reduced on MRI performed 37 days after treatment began.
  • The patient received hydroxyurea for 7 months, with symptoms remaining stable, and the tumor re-increased to almost the same size at 7 months as that at the initial examination.
  • At that time, hydroxyurea was discontinued.
  • The patient died from pulmonary edema 14 months after treatment began.
  • Pathologically, the tumor was diagnosed as a meningioma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176033.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


98. Bhattacharjee M, Bose I, Sarkar P, Banerjee C, Dutta S, Ghosh A, Mukherjee J, Acharya S, Goswami S, Mazumdar A, Chaudhuri S, Chaudhuri S: A sequential scanning of the immune efficiency in astrocytoma (Grade I to Grade Iii), meningioma and secondary glioma patients with and without therapeutic scheduling. Cancer Invest; 2006 Aug-Sep;24(5):502-13
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A sequential scanning of the immune efficiency in astrocytoma (Grade I to Grade Iii), meningioma and secondary glioma patients with and without therapeutic scheduling.
  • However, data revealing the immune status in glioma patients with sequential therapeutic interventions is missing.
  • Thus, the study aims at evaluating the sequential immune status of glioma bearing patients (Astrocytoma Grade I to Grade III) receiving conventional therapeutic measures.
  • The results were compared with the immune status of metastatic secondary glioma and meningioma patients where there is minimal immune suppression and the effect of therapeutic intervention on the above score.
  • METHODS: Functional immune parameters of peripheral blood lymphocytes were assayed by CD2 receptors enumeration through E-rosetting and lymphocyte cytotoxicity assay and assessing the generation of reactive oxygen species by NBT assay of peripheral blood macrophages in patient groups bearing Astrocytoma (Grade I to Grade III), meningioma and secondary glioma.
  • RESULTS: Patients bearing Astrocytoma (all 3 grades) showed maximum immune suppression as compared to the normal subjects, diseased meningioma controls, and secondary glioma.
  • Therapeutic interventions viz. radiotherapy, surgery and radiotherapy after surgery and chemotherapy could not recover the suppressed activity of the CD2 bearing lymphocytes and that of peripheral blood macrophages.
  • However, therapeutic scheduling could recover the functional activity of the CD8 bearing lymphocytes and the CD56 NK cells from that of tumor bearing patients.
  • CONCLUSION: Astrocytoma and not meningioma is capable of causing immunesuppression.
  • As the tumor progresses from Grade I to Grade III, a linear reduction in the functional efficacy of immunocytes is seen to occur.
  • Radiotherapy, surgery, and chemotherapy also induces an inhibitory effect towards the host immune system.
  • The inhibitory effect of tumor as well as of therapy were mainly directed towards the CD2 bearing lymphocyte population and the peripheral blood macrophage population.
  • [MeSH-major] Astrocytoma / immunology. Central Nervous System Neoplasms / immunology. Glioma / immunology. Immune Tolerance. Meningioma / immunology
  • [MeSH-minor] Antigens, CD2 / analysis. Antineoplastic Agents / adverse effects. Cytotoxicity Tests, Immunologic. Humans. Macrophages / immunology. Neoplasm Invasiveness. Phagocytosis. Radiotherapy / adverse effects. Rosette Formation. T-Lymphocytes, Cytotoxic / immunology

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939959.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD2; 0 / Antineoplastic Agents
  •  go-up   go-down


99. Richardson TT, Cohen PR: Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin. Cutis; 2000 Sep;66(3):183-8
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin.
  • In some patients, subacute cutaneous lupus erythematosus, a distinct subset of lupus erythematosus, has appeared, resolved, or both as a solid tumor-related paraneoplastic syndrome.
  • A woman in whom a meningioma was diagnosed 44 years following the onset of subacute cutaneous lupus erythematosus is described; her skin lesions improved after starting isotretinoin therapy.
  • [MeSH-major] Dermatologic Agents / therapeutic use. Isotretinoin / therapeutic use. Lupus Erythematosus, Cutaneous / complications. Lupus Erythematosus, Cutaneous / drug therapy. Meningeal Neoplasms / etiology. Meningioma / etiology
  • [MeSH-minor] Administration, Topical. Aged. Anti-Inflammatory Agents / therapeutic use. Clobetasol / therapeutic use. Female. Fluocinonide / therapeutic use. Glucocorticoids. Humans

  • Genetic Alliance. consumer health - Cutaneous Lupus Erythematosus.
  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. Clobetasol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11006852.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents; 0 / Glucocorticoids; 2W4A77YPAN / Fluocinonide; ADN79D536H / Clobetasol; EH28UP18IF / Isotretinoin
  • [Number-of-references] 36
  •  go-up   go-down


100. Wessling H, Simosono CL, Escosa-Bagé M, de Las Heras-Echeverría P: Anton's syndrome due to a giant anterior fossa meningioma. The problem of routine use of advanced diagnostic imaging in psychiatric care. Acta Neurochir (Wien); 2006 Jun;148(6):673-5; discussion 675
Genetic Alliance. consumer health - Anton's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anton's syndrome due to a giant anterior fossa meningioma. The problem of routine use of advanced diagnostic imaging in psychiatric care.
  • We present a case of blindness and Anton's syndrome in a psychiatric patient with late diagnosis of a giant frontal meningioma.
  • We conclude that MR or CT scan is indicated in psychiatric in-patients who fail to improve with standard psychiatric treatment.
  • [MeSH-major] Blindness, Cortical / etiology. Cranial Fossa, Anterior / pathology. Diagnostic Errors. Intellectual Disability / etiology. Meningeal Neoplasms / complications. Meningioma / complications
  • [MeSH-minor] Adult. Corpus Callosum / pathology. Corpus Callosum / surgery. Decompression, Surgical. Disease Progression. Epilepsy / etiology. Epilepsy / physiopathology. Frontal Lobe / pathology. Frontal Lobe / surgery. Hospitals, Psychiatric / standards. Humans. Male. Mental Competency. Mental Disorders / drug therapy. Mental Disorders / etiology. Mental Disorders / physiopathology. Neurosurgical Procedures. Optic Nerve / pathology. Schizophrenia, Disorganized / diagnosis. Schizophrenia, Disorganized / etiology. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598409.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down






Advertisement